{"relationship_key":"canon-034b6c51258b:INDICATES:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":117,"text_span":"Positive autoantibody evaluation confirms the diagnosis as autoimmune primary adrenal insufficiency (autoimmune PAI).","confidence":0.95,"supports":true}
{"relationship_key":"canon-034b6c51258b:INDICATES:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":236,"text_span":"These antibodies have since then been shown to be highly specific for autoimmune PAI in several patient cohorts, and found present in 80–90% of patients with PAI in cross-sectional studies after exclusion of known non-autoimmune causes.","confidence":0.9,"supports":true}
{"relationship_key":"canon-8ce6d4e6c70c:INDICATES:C0001623","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":127,"text_span":"A healthy person is expected to have >500 nmol/L of plasma cortisol concentration 60 minutes after 250µg cosyntropin injection.","confidence":0.9,"supports":true}
{"relationship_key":"5492:TREATS:C0001623","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":136,"text_span":"The standard medication of glucocorticoid treatment for patients with AI (primary and secondary) is hydrocortisone or cortisone acetate.","confidence":0.9,"supports":true}
{"relationship_key":"4603:TREATS:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":102,"text_span":"Patients with primary AI additionally take fludrocortisone treatment for mineralocorticoid deficiency.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:360:INCREASES_RISK:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":193,"text_span":"We recently performed the world's first GWAS on autoimmune PAI including only ~1200 patients, but which succeeded to elucidate nine genetic regions with quite remarkable risk potential for PAI.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:2505:INCREASES_RISK:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":193,"text_span":"We recently performed the world's first GWAS on autoimmune PAI including only ~1200 patients, but which succeeded to elucidate nine genetic regions with quite remarkable risk potential for PAI.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:9652:INCREASES_RISK:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":193,"text_span":"We recently performed the world's first GWAS on autoimmune PAI including only ~1200 patients, but which succeeded to elucidate nine genetic regions with quite remarkable risk potential for PAI.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:936:INCREASES_RISK:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":193,"text_span":"We recently performed the world's first GWAS on autoimmune PAI including only ~1200 patients, but which succeeded to elucidate nine genetic regions with quite remarkable risk potential for PAI.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:2600:ASSOCIATED_WITH:C0001627","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":197,"text_span":"Skov and collaborators recently showed, by analyzing 29 twin pairs with PAI, a concordance for monozygotic twins of 0.71 and a heritability of 0.97, revealing that PAI is a highly genetic disorder.","confidence":0.95,"supports":true}
{"relationship_key":"C0085859:SUBTYPE_OF:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":151,"text_span":"Autoimmune primary adrenal insufficiency is usually a polygenic disease where our information recently has increased due to genome association studies.","confidence":0.9,"supports":true}
{"relationship_key":"C0085860:SUBTYPE_OF:C0001403","document_id":"PMC10667925","section":null,"start_offset":0,"end_offset":151,"text_span":"Autoimmune primary adrenal insufficiency is usually a polygenic disease where our information recently has increased due to genome association studies.","confidence":0.9,"supports":true}
{"relationship_key":"3108:TREATS:C0221406","document_id":"PMC11128938","section":null,"start_offset":0,"end_offset":77,"text_span":"Intravenous desmopressin administration produced no ACTH or cortisol increase","confidence":0.9,"supports":true}
{"relationship_key":"3108:INCREASES:HGNC:13758","document_id":"PMC11128938","section":null,"start_offset":0,"end_offset":150,"text_span":"Inferior petrosal sinus sampling (IPSS) with desmopressin stimulation resulted in elevated central-to-peripheral ACTH ratio and prolactin co-secretion","confidence":0.9,"supports":true}
{"relationship_key":"20352:CAUSES:C0001623","document_id":"PMC11128938","section":null,"start_offset":0,"end_offset":112,"text_span":"Cabergoline was initiated, after which the patient rapidly developed transient severe adrenal insufficiency (AI)","confidence":0.9,"supports":true}
{"relationship_key":"C0001632:TREATS:C0020626","document_id":"PMC11128938","section":null,"start_offset":0,"end_offset":76,"text_span":"Bilateral adrenalectomy was performed in view of persistent hypercortisolism","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:897:ASSOCIATED_WITH:C0001430","document_id":"PMC11128938","section":null,"start_offset":0,"end_offset":178,"text_span":"The mechanism by which desmopressin stimulates ACTH secretion in CD may result from overexpression of AVPR1B receptors as well as ectopic AVPR2 receptors in corticotroph adenomas","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:898:ASSOCIATED_WITH:C0001430","document_id":"PMC11128938","section":null,"start_offset":0,"end_offset":178,"text_span":"The mechanism by which desmopressin stimulates ACTH secretion in CD may result from overexpression of AVPR1B receptors as well as ectopic AVPR2 receptors in corticotroph adenomas","confidence":0.8,"supports":true}
{"relationship_key":"1234567:TREATS:C0010481","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":55,"text_span":"pasireotide is an approved somatostatin receptor ligand","confidence":0.95,"supports":true}
{"relationship_key":"1234567:TREATS:C0010481","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":198,"text_span":"The first randomized phase III clinical trial involving 162 patients with CD treated with subcutaneous pasireotide showed urine-free cortisol (UFC) normalization at month 6 in 15–26% of the patients","confidence":0.95,"supports":true}
{"relationship_key":"1234568:TREATS:C0010481","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":101,"text_span":"levoketoconazole normalized mean urinary free cortisol (mUFC) levels in more than 50% of the patients","confidence":0.9,"supports":true}
{"relationship_key":"1234569:TREATS:C0010481","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":105,"text_span":"osilodrostat resulted in a complete response in 66% and a partial response in 9% of the enrolled patients","confidence":0.9,"supports":true}
{"relationship_key":"1234570:TREATS:C0010481","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":93,"text_span":"36–62% of corticotroph adenomas show gain-of-function mutations in the gene encoding for USP8","confidence":0.85,"supports":true}
{"relationship_key":"HGNC:12631:ASSOCIATED_WITH:C0032000","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":93,"text_span":"36–62% of corticotroph adenomas show gain-of-function mutations in the gene encoding for USP8","confidence":0.85,"supports":true}
{"relationship_key":"1234567:TARGETS:HGNC:11330","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":55,"text_span":"pasireotide is an approved somatostatin receptor ligand","confidence":0.95,"supports":true}
{"relationship_key":"1234567:TARGETS:HGNC:11333","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":55,"text_span":"pasireotide is an approved somatostatin receptor ligand","confidence":0.95,"supports":true}
{"relationship_key":"C0087111:TREATS:C0010481","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":93,"text_span":"Rates of recurrence and/or persistence of Cushing's disease after surgical treatment are high","confidence":0.9,"supports":true}
{"relationship_key":"C0201968:INDICATES:C0010481","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":198,"text_span":"The first randomized phase III clinical trial involving 162 patients with CD treated with subcutaneous pasireotide showed urine-free cortisol (UFC) normalization at month 6 in 15–26% of the patients","confidence":0.95,"supports":true}
{"relationship_key":"C0201968:INDICATES:C0010481","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":101,"text_span":"levoketoconazole normalized mean urinary free cortisol (mUFC) levels in more than 50% of the patients","confidence":0.9,"supports":true}
{"relationship_key":"284635:TARGETS:HGNC:3236","document_id":"PMC11548364","section":null,"start_offset":0,"end_offset":93,"text_span":"36–62% of corticotroph adenomas show gain-of-function mutations in the gene encoding for USP8","confidence":0.85,"supports":true}
{"relationship_key":"canon-cd261e00602b:ASSOCIATED_WITH:C0032000","document_id":"PMC11560769","section":null,"start_offset":0,"end_offset":120,"text_span":"The study by Pekul et al. emphasized the relevance of USP and TP53 mutations in pituitary tumors for prognostic guidance","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:11998:ASSOCIATED_WITH:C0032000","document_id":"PMC11560769","section":null,"start_offset":0,"end_offset":120,"text_span":"The study by Pekul et al. emphasized the relevance of USP and TP53 mutations in pituitary tumors for prognostic guidance","confidence":0.8,"supports":true}
{"relationship_key":"3168:INDICATES:C0221406","document_id":"PMC11560769","section":null,"start_offset":0,"end_offset":93,"text_span":"A meta-analysis by Giampetro et al. evaluated the use of desmopressin for diagnostic purposes","confidence":0.8,"supports":true}
{"relationship_key":"1100699:TREATS:C0010481","document_id":"PMC11560769","section":null,"start_offset":0,"end_offset":137,"text_span":"Feelders et al. demonstrated that combination of pasireotide with cabergoline can yield sustained long-term efficacy in selected patients","confidence":0.8,"supports":true}
{"relationship_key":"20352:TREATS:C0010481","document_id":"PMC11560769","section":null,"start_offset":0,"end_offset":137,"text_span":"Feelders et al. demonstrated that combination of pasireotide with cabergoline can yield sustained long-term efficacy in selected patients","confidence":0.8,"supports":true}
{"relationship_key":"C0031511:ASSOCIATED_WITH:C0221406","document_id":"PMC11685751","section":null,"start_offset":0,"end_offset":463,"text_span":"A 66-year-old woman was referred to the hospital due to pronounced weakness, loss of appetite, apathy, weight loss, newly diagnosed diabetes mellitus, and poorly controlled hypertension. The biochemical evaluation suggested ACTH-dependent hypercortisolemia with severe hypokalemia, metabolic alkalosis, and hyperglycemia. Markedly elevated levels of metanephrines, along with imaging showing a heterogeneous adrenal lesion, provided evidence for pheochromocytoma.","confidence":0.95,"supports":true}
{"relationship_key":"C0031511:ASSOCIATED_WITH:C0221406","document_id":"PMC11685751","section":null,"start_offset":0,"end_offset":152,"text_span":"Histopathological examination confirmed a pheochromocytoma; however, both anti-ACTH and anti-CRH stainings were negative, leading to a diagnosis of PCS.","confidence":0.95,"supports":true}
{"relationship_key":"C0031511:ASSOCIATED_WITH:C0011849","document_id":"PMC11685751","section":null,"start_offset":0,"end_offset":463,"text_span":"A 66-year-old woman was referred to the hospital due to pronounced weakness, loss of appetite, apathy, weight loss, newly diagnosed diabetes mellitus, and poorly controlled hypertension. The biochemical evaluation suggested ACTH-dependent hypercortisolemia with severe hypokalemia, metabolic alkalosis, and hyperglycemia. Markedly elevated levels of metanephrines, along with imaging showing a heterogeneous adrenal lesion, provided evidence for pheochromocytoma.","confidence":0.95,"supports":true}
{"relationship_key":"C0031511:ASSOCIATED_WITH:C0020538","document_id":"PMC11685751","section":null,"start_offset":0,"end_offset":463,"text_span":"A 66-year-old woman was referred to the hospital due to pronounced weakness, loss of appetite, apathy, weight loss, newly diagnosed diabetes mellitus, and poorly controlled hypertension. The biochemical evaluation suggested ACTH-dependent hypercortisolemia with severe hypokalemia, metabolic alkalosis, and hyperglycemia. Markedly elevated levels of metanephrines, along with imaging showing a heterogeneous adrenal lesion, provided evidence for pheochromocytoma.","confidence":0.95,"supports":true}
{"relationship_key":"C0031511:ASSOCIATED_WITH:C0020621","document_id":"PMC11685751","section":null,"start_offset":0,"end_offset":463,"text_span":"A 66-year-old woman was referred to the hospital due to pronounced weakness, loss of appetite, apathy, weight loss, newly diagnosed diabetes mellitus, and poorly controlled hypertension. The biochemical evaluation suggested ACTH-dependent hypercortisolemia with severe hypokalemia, metabolic alkalosis, and hyperglycemia. Markedly elevated levels of metanephrines, along with imaging showing a heterogeneous adrenal lesion, provided evidence for pheochromocytoma.","confidence":0.95,"supports":true}
{"relationship_key":"C0031511:ASSOCIATED_WITH:C0220981","document_id":"PMC11685751","section":null,"start_offset":0,"end_offset":463,"text_span":"A 66-year-old woman was referred to the hospital due to pronounced weakness, loss of appetite, apathy, weight loss, newly diagnosed diabetes mellitus, and poorly controlled hypertension. The biochemical evaluation suggested ACTH-dependent hypercortisolemia with severe hypokalemia, metabolic alkalosis, and hyperglycemia. Markedly elevated levels of metanephrines, along with imaging showing a heterogeneous adrenal lesion, provided evidence for pheochromocytoma.","confidence":0.95,"supports":true}
{"relationship_key":"C0031511:ASSOCIATED_WITH:C0020456","document_id":"PMC11685751","section":null,"start_offset":0,"end_offset":463,"text_span":"A 66-year-old woman was referred to the hospital due to pronounced weakness, loss of appetite, apathy, weight loss, newly diagnosed diabetes mellitus, and poorly controlled hypertension. The biochemical evaluation suggested ACTH-dependent hypercortisolemia with severe hypokalemia, metabolic alkalosis, and hyperglycemia. Markedly elevated levels of metanephrines, along with imaging showing a heterogeneous adrenal lesion, provided evidence for pheochromocytoma.","confidence":0.95,"supports":true}
{"relationship_key":"C0025598:INDICATES:C0031511","document_id":"PMC11685751","section":null,"start_offset":0,"end_offset":463,"text_span":"A 66-year-old woman was referred to the hospital due to pronounced weakness, loss of appetite, apathy, weight loss, newly diagnosed diabetes mellitus, and poorly controlled hypertension. The biochemical evaluation suggested ACTH-dependent hypercortisolemia with severe hypokalemia, metabolic alkalosis, and hyperglycemia. Markedly elevated levels of metanephrines, along with imaging showing a heterogeneous adrenal lesion, provided evidence for pheochromocytoma.","confidence":0.95,"supports":true}
{"relationship_key":"C0001632:TREATS:C0031511","document_id":"PMC11685751","section":null,"start_offset":0,"end_offset":338,"text_span":"The patient underwent adrenalectomy following pre-treatment with doxazosin and metyrapone, enteral feeding, protein supplementation, and insulin administration. Post-surgery, the patient did not require further antidiabetic medication, experienced gradual weight gain, improved well-being, and did not need glucocorticoid supplementation.","confidence":0.95,"supports":true}
{"relationship_key":"3616:TREATS:C0031511","document_id":"PMC11685751","section":null,"start_offset":0,"end_offset":338,"text_span":"The patient underwent adrenalectomy following pre-treatment with doxazosin and metyrapone, enteral feeding, protein supplementation, and insulin administration. Post-surgery, the patient did not require further antidiabetic medication, experienced gradual weight gain, improved well-being, and did not need glucocorticoid supplementation.","confidence":0.95,"supports":true}
{"relationship_key":"6876:TREATS:C0221406","document_id":"PMC11685751","section":null,"start_offset":0,"end_offset":338,"text_span":"The patient underwent adrenalectomy following pre-treatment with doxazosin and metyrapone, enteral feeding, protein supplementation, and insulin administration. Post-surgery, the patient did not require further antidiabetic medication, experienced gradual weight gain, improved well-being, and did not need glucocorticoid supplementation.","confidence":0.95,"supports":true}
{"relationship_key":"6876:TREATS:C0221406","document_id":"PMC11685751","section":null,"start_offset":0,"end_offset":321,"text_span":"A rapid decrease in the level of cortisol, ACTH, and metanephrines upon initiation of metyrapone treatment suggests the existence of a glucocorticoid-dependent positive feedback loop that potentiated ACTH release and created a destructive cycle with rapid exacerbation of both hypercortisolemia and hypercatecholaminemia.","confidence":0.9,"supports":true}
{"relationship_key":"5856:TREATS:C0011849","document_id":"PMC11685751","section":null,"start_offset":0,"end_offset":338,"text_span":"The patient underwent adrenalectomy following pre-treatment with doxazosin and metyrapone, enteral feeding, protein supplementation, and insulin administration. Post-surgery, the patient did not require further antidiabetic medication, experienced gradual weight gain, improved well-being, and did not need glucocorticoid supplementation.","confidence":0.95,"supports":true}
{"relationship_key":"C0001655:CAUSES:C0010481","document_id":"PMC11779774","section":null,"start_offset":0,"end_offset":163,"text_span":"Cushing's disease (CD) is caused by an adrenocorticotropic hormone (ACTH)-producing pituitary adenoma and is the most common cause of endogenous Cushing's syndrome","confidence":0.95,"supports":true}
{"relationship_key":"C0032000:CAUSES:C0010481","document_id":"PMC11779774","section":null,"start_offset":0,"end_offset":163,"text_span":"Cushing's disease (CD) is caused by an adrenocorticotropic hormone (ACTH)-producing pituitary adenoma and is the most common cause of endogenous Cushing's syndrome","confidence":0.95,"supports":true}
{"relationship_key":"C0010481:ASSOCIATED_WITH:C0020538","document_id":"PMC11779774","section":null,"start_offset":0,"end_offset":270,"text_span":"Despite its rare occurrence, the disorder is associated with commonly encountered comorbidities including hypertension, obesity, dyslipidemia, atherosclerosis, hypercoagulability, osteoporosis and fractures, impaired glucose metabolism, and immune and growth suppression","confidence":0.9,"supports":true}
{"relationship_key":"C0010481:ASSOCIATED_WITH:C0028754","document_id":"PMC11779774","section":null,"start_offset":0,"end_offset":270,"text_span":"Despite its rare occurrence, the disorder is associated with commonly encountered comorbidities including hypertension, obesity, dyslipidemia, atherosclerosis, hypercoagulability, osteoporosis and fractures, impaired glucose metabolism, and immune and growth suppression","confidence":0.9,"supports":true}
{"relationship_key":"C0010481:ASSOCIATED_WITH:C0242339","document_id":"PMC11779774","section":null,"start_offset":0,"end_offset":270,"text_span":"Despite its rare occurrence, the disorder is associated with commonly encountered comorbidities including hypertension, obesity, dyslipidemia, atherosclerosis, hypercoagulability, osteoporosis and fractures, impaired glucose metabolism, and immune and growth suppression","confidence":0.9,"supports":true}
{"relationship_key":"C0010481:ASSOCIATED_WITH:C0004153","document_id":"PMC11779774","section":null,"start_offset":0,"end_offset":270,"text_span":"Despite its rare occurrence, the disorder is associated with commonly encountered comorbidities including hypertension, obesity, dyslipidemia, atherosclerosis, hypercoagulability, osteoporosis and fractures, impaired glucose metabolism, and immune and growth suppression","confidence":0.9,"supports":true}
{"relationship_key":"C0010481:ASSOCIATED_WITH:C0029456","document_id":"PMC11779774","section":null,"start_offset":0,"end_offset":270,"text_span":"Despite its rare occurrence, the disorder is associated with commonly encountered comorbidities including hypertension, obesity, dyslipidemia, atherosclerosis, hypercoagulability, osteoporosis and fractures, impaired glucose metabolism, and immune and growth suppression","confidence":0.9,"supports":true}
{"relationship_key":"6135:TREATS:C0010481","document_id":"PMC11779774","section":null,"start_offset":0,"end_offset":128,"text_span":"Ketoconazole was the most frequently used drug, with a median rate of usage of 26.5% (5-66.7) of those receiving medical therapy","confidence":0.95,"supports":true}
{"relationship_key":"6135:TREATS:C0010481","document_id":"PMC11779774","section":null,"start_offset":0,"end_offset":97,"text_span":"The median biochemical control rate of ketoconazole provided by 7 centers was 76% (range: 20–100)","confidence":0.95,"supports":true}
{"relationship_key":"6876:TREATS:C0010481","document_id":"PMC11779774","section":null,"start_offset":0,"end_offset":146,"text_span":"Biochemical control rates with pasireotide and metyrapone, available from 5 centers, were 80% (range: 50–100) and 60% (range: 10–80), respectively","confidence":0.95,"supports":true}
{"relationship_key":"1234995:TREATS:C0010481","document_id":"PMC11779774","section":null,"start_offset":0,"end_offset":146,"text_span":"Biochemical control rates with pasireotide and metyrapone, available from 5 centers, were 80% (range: 50–100) and 60% (range: 10–80), respectively","confidence":0.95,"supports":true}
{"relationship_key":"2378234:TREATS:C0010481","document_id":"PMC11779774","section":null,"start_offset":0,"end_offset":160,"text_span":"The rate of biochemical control with osilodrostat and combination therapy provided by 4 centers were 65% (range: 33–100) and 73.8% (range: 50–100), respectively","confidence":0.95,"supports":true}
{"relationship_key":"C0342482:SUBTYPE_OF:C0001627","document_id":"PMC11795198","section":null,"start_offset":0,"end_offset":125,"text_span":"Of all congenital adrenal hyperplasia (CAH), 95% to 99% is 21-hydroxylase deficiency (21OHD), an autosomal recessive disease.","confidence":0.95,"supports":true}
{"relationship_key":"C0342482:SUBTYPE_OF:C0001627","document_id":"PMC11795198","section":null,"start_offset":0,"end_offset":117,"text_span":"The predominant enzyme deficiency that accounts for 95% to 99% of all CAH cases is 21-hydroxylase deficiency (21OHD).","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:2600:ENCODES:canon-69487f729f41","document_id":"PMC11795198","section":null,"start_offset":0,"end_offset":148,"text_span":"21OHD is due to an insufficiency of 21-hydroxylase enzyme, which is encoded by the CYP21A2 gene and involved in cortisol and aldosterone production.","confidence":0.95,"supports":true}
{"relationship_key":"canon-69487f729f41:INVOLVED_IN:C0020268","document_id":"PMC11795198","section":null,"start_offset":0,"end_offset":148,"text_span":"21OHD is due to an insufficiency of 21-hydroxylase enzyme, which is encoded by the CYP21A2 gene and involved in cortisol and aldosterone production.","confidence":0.95,"supports":true}
{"relationship_key":"canon-69487f729f41:INVOLVED_IN:C0002006","document_id":"PMC11795198","section":null,"start_offset":0,"end_offset":148,"text_span":"21OHD is due to an insufficiency of 21-hydroxylase enzyme, which is encoded by the CYP21A2 gene and involved in cortisol and aldosterone production.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:2600:ASSOCIATED_WITH:C0342482","document_id":"PMC11795198","section":null,"start_offset":0,"end_offset":148,"text_span":"21OHD is due to an insufficiency of 21-hydroxylase enzyme, which is encoded by the CYP21A2 gene and involved in cortisol and aldosterone production.","confidence":0.95,"supports":true}
{"relationship_key":"canon-c98e6b01c1ee:SUBTYPE_OF:C0342482","document_id":"PMC11795198","section":null,"start_offset":0,"end_offset":240,"text_span":"21OHD comprises 2 groups, the classic and nonclassic (NC) form. Classic 21OHD is further divided into salt-wasting (SW) (cortisol and aldosterone deficiency) and simple virilizing (SV) phenotype (cortisol and milder aldosterone deficiency).","confidence":0.95,"supports":true}
{"relationship_key":"canon-bc4ffb24fce9:SUBTYPE_OF:C0342482","document_id":"PMC11795198","section":null,"start_offset":0,"end_offset":240,"text_span":"21OHD comprises 2 groups, the classic and nonclassic (NC) form. Classic 21OHD is further divided into salt-wasting (SW) (cortisol and aldosterone deficiency) and simple virilizing (SV) phenotype (cortisol and milder aldosterone deficiency).","confidence":0.95,"supports":true}
{"relationship_key":"canon-16694cc8d051:SUBTYPE_OF:C0342482","document_id":"PMC11795198","section":null,"start_offset":0,"end_offset":240,"text_span":"21OHD comprises 2 groups, the classic and nonclassic (NC) form. Classic 21OHD is further divided into salt-wasting (SW) (cortisol and aldosterone deficiency) and simple virilizing (SV) phenotype (cortisol and milder aldosterone deficiency).","confidence":0.95,"supports":true}
{"relationship_key":"canon-6fadd12fd08b:TREATS:C0001627","document_id":"PMC11795198","section":null,"start_offset":0,"end_offset":183,"text_span":"The main therapies in CAH are glucocorticoids to replace the deficiency and normalize the adrenal androgens and mineralocorticoids, compulsory in SW CAH but often also used in SV CAH.","confidence":0.95,"supports":true}
{"relationship_key":"4603:TREATS:canon-c98e6b01c1ee","document_id":"PMC11795198","section":null,"start_offset":0,"end_offset":209,"text_span":"Mineralocorticoids, in the form of fludrocortisone, are particularly important prior to (since they may induce ovulation) and during pregnancy in patients with SW CAH but may also be used in those with SV CAH.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11976:ASSOCIATED_WITH:canon-9b45feabf398","document_id":"PMC11795198","section":null,"start_offset":0,"end_offset":235,"text_span":"The genetic cause of CAH-X syndrome is a recombination event between TNXB and its pseudogene TNXA. The resulting 30 kb deletion includes the entire CYP21A2 gene sequence and part of the TNXB gene and produces a chimeric TNXA/TNXB gene.","confidence":0.95,"supports":true}
{"relationship_key":"canon-9b45feabf398:ASSOCIATED_WITH:C0013720","document_id":"PMC11795198","section":null,"start_offset":0,"end_offset":212,"text_span":"The functional consequence of this rearrangement is the complete absence of the 21OH enzyme and the deficiency of tenascin-X, while the resulting phenotype is a hypermobility form of Ehlers-Danlos syndrome (EDS).","confidence":0.95,"supports":true}
{"relationship_key":"3264:INCREASES_RISK:C0338656","document_id":"PMC12035109","section":null,"start_offset":0,"end_offset":139,"text_span":"Prolonged high-concentration cortisol exposure may impair cognitive function, but its mechanisms and risk factors remain unclear in humans.","confidence":0.9,"supports":true}
{"relationship_key":"3264:INCREASES_RISK:C0338656","document_id":"PMC12035109","section":null,"start_offset":0,"end_offset":258,"text_span":"High cortisol exerts its effects through glucocorticoid receptors and mineralocorticoid receptors in the hippocampus, mediating neurophysiological responses. Prolonged activation may lead to neuronal damage, reduced neuroplasticity, and cognitive impairment.","confidence":0.9,"supports":true}
{"relationship_key":"C0010481:ASSOCIATED_WITH:C0338656","document_id":"PMC12035109","section":null,"start_offset":0,"end_offset":179,"text_span":"Patients with Cushing's disease often experience cognitive impairments, with clinical manifestations including memory decline, attention deficits, and impaired executive function.","confidence":0.9,"supports":true}
{"relationship_key":"canon-439b2924a798:INDICATES:C0338656","document_id":"PMC12035109","section":null,"start_offset":0,"end_offset":152,"text_span":"Cortisol AM/PM ratio, 8 a.m. cortisol concentration, body mass index, and fasting plasma glucose were significant risk factors for cognitive impairment.","confidence":0.95,"supports":true}
{"relationship_key":"canon-dfff01e52570:INDICATES:C0338656","document_id":"PMC12035109","section":null,"start_offset":0,"end_offset":152,"text_span":"Cortisol AM/PM ratio, 8 a.m. cortisol concentration, body mass index, and fasting plasma glucose were significant risk factors for cognitive impairment.","confidence":0.95,"supports":true}
{"relationship_key":"canon-5a0632dad48d:INCREASES_RISK:C0338656","document_id":"PMC12035109","section":null,"start_offset":0,"end_offset":152,"text_span":"Cortisol AM/PM ratio, 8 a.m. cortisol concentration, body mass index, and fasting plasma glucose were significant risk factors for cognitive impairment.","confidence":0.95,"supports":true}
{"relationship_key":"canon-5a0632dad48d:INCREASES_RISK:C0338656","document_id":"PMC12035109","section":null,"start_offset":0,"end_offset":171,"text_span":"Increased BMI was identified as an independent risk factor for cognitive impairment, likely due to chronic inflammation and oxidative stress caused by metabolic disorders.","confidence":0.85,"supports":true}
{"relationship_key":"canon-75b09cb2f61d:INCREASES_RISK:C0338656","document_id":"PMC12035109","section":null,"start_offset":0,"end_offset":152,"text_span":"Cortisol AM/PM ratio, 8 a.m. cortisol concentration, body mass index, and fasting plasma glucose were significant risk factors for cognitive impairment.","confidence":0.95,"supports":true}
{"relationship_key":"canon-75b09cb2f61d:INCREASES_RISK:C0338656","document_id":"PMC12035109","section":null,"start_offset":0,"end_offset":220,"text_span":"High blood glucose was another critical risk factor, potentially affecting cognitive function through various mechanisms: prolonged hyperglycemia can lead to cerebrovascular damage and impaired blood supply to the brain.","confidence":0.85,"supports":true}
{"relationship_key":"3264:AFFECTS:C0019564","document_id":"PMC12035109","section":null,"start_offset":0,"end_offset":258,"text_span":"High cortisol exerts its effects through glucocorticoid receptors and mineralocorticoid receptors in the hippocampus, mediating neurophysiological responses. Prolonged activation may lead to neuronal damage, reduced neuroplasticity, and cognitive impairment.","confidence":0.9,"supports":true}
{"relationship_key":"2378234:TREATS:C0010481","document_id":"PMC12055610","section":null,"start_offset":0,"end_offset":169,"text_span":"More patients who continued osilodrostat maintained a complete response without any dose increases during this period compared with those on placebo (86.1% versus 29.4%)","confidence":0.9,"supports":true}
{"relationship_key":"2378234:INHIBITS:canon-e2014b8482c1","document_id":"PMC12055610","section":null,"start_offset":0,"end_offset":126,"text_span":"Osilodrostat is a potent inhibitor of 11-beta-hydroxylase, an enzyme that catalyses cortisol biosynthesis in the adrenal gland","confidence":0.95,"supports":true}
{"relationship_key":"C0010481:ASSOCIATED_WITH:C0020268","document_id":"PMC12055610","section":null,"start_offset":0,"end_offset":113,"text_span":"Endogenous Cushing syndrome denotes a group of rare diseases resulting from the body's over-excretion of cortisol","confidence":0.9,"supports":true}
{"relationship_key":"C0221406:SUBTYPE_OF:C0010481","document_id":"PMC12055610","section":null,"start_offset":0,"end_offset":113,"text_span":"Endogenous Cushing syndrome denotes a group of rare diseases resulting from the body's over-excretion of cortisol","confidence":0.9,"supports":true}
{"relationship_key":"2378234:CAUSES:canon-12145d9d4c37","document_id":"PMC12055610","section":null,"start_offset":0,"end_offset":99,"text_span":"Hypocortisolism-related adverse events occurred in 70/138 (51%) of patients across the entire study","confidence":0.9,"supports":true}
{"relationship_key":"2378234:CAUSES:canon-6d71754c08d3","document_id":"PMC12055610","section":null,"start_offset":0,"end_offset":172,"text_span":"The most common adverse effects reported in the osilodrostat continuation group during the randomised withdrawal period were nausea (11%), arthralgia (8%) and headache (8%)","confidence":0.9,"supports":true}
{"relationship_key":"2378234:CAUSES:canon-78f2896becae","document_id":"PMC12055610","section":null,"start_offset":0,"end_offset":172,"text_span":"The most common adverse effects reported in the osilodrostat continuation group during the randomised withdrawal period were nausea (11%), arthralgia (8%) and headache (8%)","confidence":0.9,"supports":true}
{"relationship_key":"2378234:CAUSES:canon-4817bfc97f1c","document_id":"PMC12055610","section":null,"start_offset":0,"end_offset":172,"text_span":"The most common adverse effects reported in the osilodrostat continuation group during the randomised withdrawal period were nausea (11%), arthralgia (8%) and headache (8%)","confidence":0.9,"supports":true}
{"relationship_key":"C0010481:ASSOCIATED_WITH:C0020268","document_id":"PMC12187266","section":null,"start_offset":0,"end_offset":214,"text_span":"Cushing syndrome (CS) is a rare endocrine disorder characterized by excessive secretion of glucocorticoids, leading to a variety of clinical manifestations, comorbidities, and increased mortality despite treatment.","confidence":0.95,"supports":true}
{"relationship_key":"C0011777:INDICATES:C0010481","document_id":"PMC12187266","section":null,"start_offset":0,"end_offset":189,"text_span":"The correlation graph shows that CS has strong positive relationships with 2 mg (78.8%), 1 mg (76.9%), and mc (72.1%), and moderate positive correlations with 8 mg (45%) and saliva (45.4%).","confidence":0.95,"supports":true}
{"relationship_key":"canon-c058cf7d4d67:INDICATES:C0010481","document_id":"PMC12187266","section":null,"start_offset":0,"end_offset":189,"text_span":"The correlation graph shows that CS has strong positive relationships with 2 mg (78.8%), 1 mg (76.9%), and mc (72.1%), and moderate positive correlations with 8 mg (45%) and saliva (45.4%).","confidence":0.95,"supports":true}
{"relationship_key":"C1278073:INDICATES:C0010481","document_id":"PMC12187266","section":null,"start_offset":0,"end_offset":189,"text_span":"The correlation graph shows that CS has strong positive relationships with 2 mg (78.8%), 1 mg (76.9%), and mc (72.1%), and moderate positive correlations with 8 mg (45%) and saliva (45.4%).","confidence":0.95,"supports":true}
{"relationship_key":"canon-5ec27034a744:TREATS:C0010481","document_id":"PMC12187266","section":null,"start_offset":0,"end_offset":145,"text_span":"We developed a linear mathematical model with high predictive ability, achieving a classification accuracy of 97.03% and a Kappa value of 94.05%.","confidence":0.98,"supports":true}
{"relationship_key":"C0221406:SUBTYPE_OF:C0010481","document_id":"PMC12187266","section":null,"start_offset":0,"end_offset":91,"text_span":"PC is the most common cause of Cushing syndrome and is also referred to as Cushing disease.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:ASSOCIATED_WITH:C0009324","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":153,"text_span":"The mRNA expression levels of ST3Gal1 in the mucosal tissue of individuals diagnosed with UC were significantly higher than those in healthy colon mucosa","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:INCREASES_RISK:canon-8343e5df79cd","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":151,"text_span":"ST3Gal1 knockdown in the IEC monolayer increased the barrier function, whereas its overexpression resulted in intestinal barrier function deterioration","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:10861:INCREASES_RISK:canon-8343e5df79cd","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":144,"text_span":"The TEER levels in the ST3Gal1-sh3/IEC group were significantly higher than those in the IEC and sh-Ctr/IEC groups after stimulation with 2% DSS","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:7512","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":186,"text_span":"ST3Gal1 knockdown in IECs significantly increased the mRNA levels of MUC2, TFF3 and CDX2, but significantly decreased the mRNA levels of STAT3 in the inflamed stable triple culture model","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:11757","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":186,"text_span":"ST3Gal1 knockdown in IECs significantly increased the mRNA levels of MUC2, TFF3 and CDX2, but significantly decreased the mRNA levels of STAT3 in the inflamed stable triple culture model","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:1806","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":186,"text_span":"ST3Gal1 knockdown in IECs significantly increased the mRNA levels of MUC2, TFF3 and CDX2, but significantly decreased the mRNA levels of STAT3 in the inflamed stable triple culture model","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:11364","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":186,"text_span":"ST3Gal1 knockdown in IECs significantly increased the mRNA levels of MUC2, TFF3 and CDX2, but significantly decreased the mRNA levels of STAT3 in the inflamed stable triple culture model","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:5992","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":134,"text_span":"knockdown of ST3Gal1 significantly reduced the mRNA expression levels of IL-1β, IL-6 and IL-8 in the inflamed intestinal IEC monolayer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:5992","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":150,"text_span":"the overexpression of ST3Gal1 in ST3Gal1-OE/IEC cells significantly elevated the mRNA levels of IL-1β, IL-6 and IL-8 within the inflamed IEC monolayer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:5992","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":197,"text_span":"correlation analyses revealed positive correlations between ST3Gal1 mRNA expression and the expression levels of the cytokines IL-1β, IL-6, IL-8 and STAT3 in the lesional mucosa of patients with UC","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:6018","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":134,"text_span":"knockdown of ST3Gal1 significantly reduced the mRNA expression levels of IL-1β, IL-6 and IL-8 in the inflamed intestinal IEC monolayer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:6018","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":150,"text_span":"the overexpression of ST3Gal1 in ST3Gal1-OE/IEC cells significantly elevated the mRNA levels of IL-1β, IL-6 and IL-8 within the inflamed IEC monolayer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:6018","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":197,"text_span":"correlation analyses revealed positive correlations between ST3Gal1 mRNA expression and the expression levels of the cytokines IL-1β, IL-6, IL-8 and STAT3 in the lesional mucosa of patients with UC","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:6025","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":134,"text_span":"knockdown of ST3Gal1 significantly reduced the mRNA expression levels of IL-1β, IL-6 and IL-8 in the inflamed intestinal IEC monolayer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:6025","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":150,"text_span":"the overexpression of ST3Gal1 in ST3Gal1-OE/IEC cells significantly elevated the mRNA levels of IL-1β, IL-6 and IL-8 within the inflamed IEC monolayer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:REGULATES:HGNC:6025","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":197,"text_span":"correlation analyses revealed positive correlations between ST3Gal1 mRNA expression and the expression levels of the cytokines IL-1β, IL-6, IL-8 and STAT3 in the lesional mucosa of patients with UC","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:10861:CATALYZES:canon-64e4976e4d52","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":151,"text_span":"ST3Gal1 knockdown in the IEC monolayer increased the barrier function, whereas its overexpression resulted in intestinal barrier function deterioration","confidence":0.95,"supports":true}
{"relationship_key":"canon-42c7ec020dd5:INDUCES:C0009324","document_id":"PMC12750049","section":null,"start_offset":0,"end_offset":144,"text_span":"The TEER levels in the ST3Gal1-sh3/IEC group were significantly higher than those in the IEC and sh-Ctr/IEC groups after stimulation with 2% DSS","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:9581:INCREASES_RISK:C0476089","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":141,"text_span":"PTBP1 knockdown significantly suppressed tumor growth in vivo and markedly reduced Ki67 protein levels in the corresponding xenograft tissues","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9581:ASSOCIATED_WITH:C4277695","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":142,"text_span":"PTBP1 knockdown significantly increased ROS levels, reduced intracellular GSH concentrations, and elevated levels of both MDA and ferrous ions","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9581:ASSOCIATED_WITH:C4277695","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":120,"text_span":"PTBP1 knockdown significantly upregulated the expression of ACSL4, while downregulating the expression of GPX4 and HSP27","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9581:ASSOCIATED_WITH:HGNC:11059","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":136,"text_span":"The fold enrichment of SLC7A11 mRNA in anti-PTBP1 immunoprecipitations revealed approximately a four-fold increase in SLC7A11 enrichment","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9581:ASSOCIATED_WITH:HGNC:11059","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":79,"text_span":"The half-life of SLC7A11 mRNA was significantly shortened upon PTBP1 disruption","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11059:ASSOCIATED_WITH:C4277695","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":138,"text_span":"SLC7A11 restoration partially but significantly rescued cell viability and substantially diminished PTBP1 knockdown-induced ROS production","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:4556:ASSOCIATED_WITH:C4277695","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":120,"text_span":"PTBP1 knockdown significantly upregulated the expression of ACSL4, while downregulating the expression of GPX4 and HSP27","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:3571:ASSOCIATED_WITH:C4277695","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":120,"text_span":"PTBP1 knockdown significantly upregulated the expression of ACSL4, while downregulating the expression of GPX4 and HSP27","confidence":0.95,"supports":true}
{"relationship_key":"1797886:ASSOCIATED_WITH:C4277695","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":142,"text_span":"PTBP1 knockdown significantly increased ROS levels, reduced intracellular GSH concentrations, and elevated levels of both MDA and ferrous ions","confidence":0.95,"supports":true}
{"relationship_key":"1797887:ASSOCIATED_WITH:C4277695","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":142,"text_span":"PTBP1 knockdown significantly increased ROS levels, reduced intracellular GSH concentrations, and elevated levels of both MDA and ferrous ions","confidence":0.95,"supports":true}
{"relationship_key":"canon-7ed40426f8d8:INCREASES_RISK:C0024623","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":131,"text_span":"H. pylori infection promoted phosphorylation of JAK2 and STAT3, thereby activating the EMT pathway, in which YY1 played a key role.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:16848:ASSOCIATED_WITH:C0024623","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":159,"text_span":"YY1 was highly expressed in gastric cancer tissues and cells. Kaplan-Meier survival curves indicated that high YY1 expression correlated with a poor prognosis.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:16848:ACTIVATES:HGNC:6192","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":72,"text_span":"YY1 and JAK2 interaction was validated by chromatin immunoprecipitation.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:6192:ACTIVATES:HGNC:11364","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":131,"text_span":"H. pylori infection promoted phosphorylation of JAK2 and STAT3, thereby activating the EMT pathway, in which YY1 played a key role.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:16848:PROMOTES:canon-90db8977a401","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":131,"text_span":"H. pylori infection promoted phosphorylation of JAK2 and STAT3, thereby activating the EMT pathway, in which YY1 played a key role.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:16848:PROMOTES:canon-90db8977a401","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":121,"text_span":"YY1 knockdown or pharmacological inhibition reversed EMT and suppressed gastric cancer cell proliferation and metastasis.","confidence":0.9,"supports":true}
{"relationship_key":"canon-7ed40426f8d8:UPREGULATES:HGNC:16848","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":131,"text_span":"H. pylori infection promoted phosphorylation of JAK2 and STAT3, thereby activating the EMT pathway, in which YY1 played a key role.","confidence":0.9,"supports":true}
{"relationship_key":"C0389995:INHIBITS:HGNC:6192","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":121,"text_span":"YY1 knockdown or pharmacological inhibition reversed EMT and suppressed gastric cancer cell proliferation and metastasis.","confidence":0.9,"supports":true}
{"relationship_key":"canon-d5d158e34c24:ACTIVATES:HGNC:6192","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":121,"text_span":"YY1 knockdown or pharmacological inhibition reversed EMT and suppressed gastric cancer cell proliferation and metastasis.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:9563:INCREASES_RISK:C0152013","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":223,"text_span":"PSMD14 demonstrates elevated mRNA expression across multiple cancer types compared to normal tissues. In lung adenocarcinoma (LUAD), PSMD14 is upregulated not only at the transcriptional level but also at the protein level.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:INCREASES_RISK:C0152013","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":313,"text_span":"Kaplan–Meier survival analysis demonstrated that patients with high PSMD14 expression had significantly worse overall survival (OS, p = 0.003), disease-specific survival (DSS, p = 0.001), progression-free interval (PFI, p < 0.001), and disease-free interval (DFI, p < 0.001) compared to those with low expression.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:ASSOCIATED_WITH:HGNC:5012","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":279,"text_span":"Using co-immunoprecipitation (Co-IP) assays, we confirmed a specific interaction between PSMD14 and HMMR. Subsequent knockdown and overexpression of PSMD14 in LUAD cell lines demonstrated that HMMR expression is positively regulated by PSMD14 at both the mRNA and protein levels.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:REGULATES:HGNC:5012","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":279,"text_span":"Using co-immunoprecipitation (Co-IP) assays, we confirmed a specific interaction between PSMD14 and HMMR. Subsequent knockdown and overexpression of PSMD14 in LUAD cell lines demonstrated that HMMR expression is positively regulated by PSMD14 at both the mRNA and protein levels.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:REGULATES:HGNC:5012","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":158,"text_span":"PSMD14 knockdown markedly enhanced HMMR ubiquitination, whereas its overexpression reduced it. PSMD14 primarily cleaved K63-linked ubiquitin chains from HMMR.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:ACTIVATES:HGNC:11766","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":264,"text_span":"PSMD14 knockdown reduced TGF-β, p-Smad2/3 phosphorylation, and CD44 expression, whereas PSMD14 overexpression increased these markers. Similarly, PSMD14 knockdown decreased phosphorylation of mTOR, PI3K, and AKT, while its overexpression enhanced their activation.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:9563:ACTIVATES:HGNC:8975","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":264,"text_span":"PSMD14 knockdown reduced TGF-β, p-Smad2/3 phosphorylation, and CD44 expression, whereas PSMD14 overexpression increased these markers. Similarly, PSMD14 knockdown decreased phosphorylation of mTOR, PI3K, and AKT, while its overexpression enhanced their activation.","confidence":0.95,"supports":true}
{"relationship_key":"canon-34bdbb6fc6bc:TREATS:C0152013","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":181,"text_span":"The PSMD14 inhibitor Capzimin exhibited potent anti-tumor effects in vitro and in vivo, and combination therapy with the TGF-β inhibitor galunisertib demonstrated enhanced efficacy.","confidence":0.95,"supports":true}
{"relationship_key":"1598392:TREATS:C0152013","document_id":"PMC_extracted","section":null,"start_offset":0,"end_offset":181,"text_span":"The PSMD14 inhibitor Capzimin exhibited potent anti-tumor effects in vitro and in vivo, and combination therapy with the TGF-β inhibitor galunisertib demonstrated enhanced efficacy.","confidence":0.95,"supports":true}
{"relationship_key":"canon-2bc9f11f101e:INDICATES:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":380,"text_span":"DDR-IF-high tumors were characterized by a distinct biological profile, including (i) transcriptional exhaustion of the cGAS-STING innate immune pathway (p < 0.001), (ii) significantly reduced CD8+ T cell infiltration (2.3-fold fewer, p = 0.004), and (iii) a superior pooled objective response rate to PARP-ICB combinations (42% vs 18%; risk ratio 2.3, 95% CI 1.3-4.2; p = 0.003).","confidence":0.95,"supports":true}
{"relationship_key":"1298331:TREATS:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":380,"text_span":"DDR-IF-high tumors were characterized by a distinct biological profile, including (i) transcriptional exhaustion of the cGAS-STING innate immune pathway (p < 0.001), (ii) significantly reduced CD8+ T cell infiltration (2.3-fold fewer, p = 0.004), and (iii) a superior pooled objective response rate to PARP-ICB combinations (42% vs 18%; risk ratio 2.3, 95% CI 1.3-4.2; p = 0.003).","confidence":0.95,"supports":true}
{"relationship_key":"1298331:TREATS:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":252,"text_span":"In the independent MSK-IMPACT validation cohort (n=152), the DDR-IF score successfully stratified patients, with DDR-IF-high status being associated with significantly improved progression-free survival on PARP-ICB regimens (HR 0.45, 95% CI 0.22-0.91).","confidence":0.9,"supports":true}
{"relationship_key":"canon-1c7e46950620:TREATS:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":380,"text_span":"DDR-IF-high tumors were characterized by a distinct biological profile, including (i) transcriptional exhaustion of the cGAS-STING innate immune pathway (p < 0.001), (ii) significantly reduced CD8+ T cell infiltration (2.3-fold fewer, p = 0.004), and (iii) a superior pooled objective response rate to PARP-ICB combinations (42% vs 18%; risk ratio 2.3, 95% CI 1.3-4.2; p = 0.003).","confidence":0.95,"supports":true}
{"relationship_key":"canon-1c7e46950620:TREATS:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":252,"text_span":"In the independent MSK-IMPACT validation cohort (n=152), the DDR-IF score successfully stratified patients, with DDR-IF-high status being associated with significantly improved progression-free survival on PARP-ICB regimens (HR 0.45, 95% CI 0.22-0.91).","confidence":0.9,"supports":true}
{"relationship_key":"canon-7ae89029ace8:ASSOCIATED_WITH:canon-2bc9f11f101e","document_id":"extracted","section":null,"start_offset":0,"end_offset":167,"text_span":"The score, constructed using elastic-net regression, incorporates homologous recombination deficiency (HRD), tumor mutational burden (TMB), and STING pathway activity.","confidence":0.9,"supports":true}
{"relationship_key":"canon-80ccfebc36f3:ASSOCIATED_WITH:canon-2bc9f11f101e","document_id":"extracted","section":null,"start_offset":0,"end_offset":167,"text_span":"The score, constructed using elastic-net regression, incorporates homologous recombination deficiency (HRD), tumor mutational burden (TMB), and STING pathway activity.","confidence":0.9,"supports":true}
{"relationship_key":"canon-a7945ea5020c:ASSOCIATED_WITH:canon-2bc9f11f101e","document_id":"extracted","section":null,"start_offset":0,"end_offset":167,"text_span":"The score, constructed using elastic-net regression, incorporates homologous recombination deficiency (HRD), tumor mutational burden (TMB), and STING pathway activity.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:795:ASSOCIATED_WITH:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":202,"text_span":"Recent global epidemiological data (2024) confirm that more than 70% of ES-SCLC cases carry at least one actionable DDR defect, with frequent alterations in genes such as ATM (11.2%) and BRCA1/2 (6.7%).","confidence":0.85,"supports":true}
{"relationship_key":"HGNC:1100:ASSOCIATED_WITH:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":202,"text_span":"Recent global epidemiological data (2024) confirm that more than 70% of ES-SCLC cases carry at least one actionable DDR defect, with frequent alterations in genes such as ATM (11.2%) and BRCA1/2 (6.7%).","confidence":0.85,"supports":true}
{"relationship_key":"HGNC:1101:ASSOCIATED_WITH:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":202,"text_span":"Recent global epidemiological data (2024) confirm that more than 70% of ES-SCLC cases carry at least one actionable DDR defect, with frequent alterations in genes such as ATM (11.2%) and BRCA1/2 (6.7%).","confidence":0.85,"supports":true}
{"relationship_key":"canon-c83c06b60e40:ASSOCIATED_WITH:C0149925","document_id":"extracted","section":null,"start_offset":0,"end_offset":202,"text_span":"Recent global epidemiological data (2024) confirm that more than 70% of ES-SCLC cases carry at least one actionable DDR defect, with frequent alterations in genes such as ATM (11.2%) and BRCA1/2 (6.7%).","confidence":0.85,"supports":true}
{"relationship_key":"HGNC:1100:INCREASES_RISK:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":133,"text_span":"approximately 5-15% of cases linked to pathogenic variants primarily in BRCA1 or BRCA2. These mutations greatly increase cancer risks","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:1100:INCREASES_RISK:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":82,"text_span":"Carriers of BRCA1 mutation may have higher risk of both breast and ovarian cancers","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:1101:INCREASES_RISK:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":133,"text_span":"approximately 5-15% of cases linked to pathogenic variants primarily in BRCA1 or BRCA2. These mutations greatly increase cancer risks","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:1101:INCREASES_RISK:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":182,"text_span":"Carriers of pathogenic BRCA2 variants have a lifetime risk of developing breast cancer ranging from 38% to 84%, while the risk of developing ovarian cancer ranges from 16.5% to 27.0%","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:1100:INCREASES_RISK:C0029925","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":82,"text_span":"Carriers of BRCA1 mutation may have higher risk of both breast and ovarian cancers","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:1101:INCREASES_RISK:C0029925","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":182,"text_span":"Carriers of pathogenic BRCA2 variants have a lifetime risk of developing breast cancer ranging from 38% to 84%, while the risk of developing ovarian cancer ranges from 16.5% to 27.0%","confidence":0.9,"supports":true}
{"relationship_key":"C0024485:INDICATES:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":140,"text_span":"Annual magnetic resonance imaging (MRI) remains the most sensitive screening tool for early breast cancer detection in high-risk individuals","confidence":0.9,"supports":true}
{"relationship_key":"C0360135:TREATS:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":118,"text_span":"Selective estrogen receptor modulators (SERMs) and aromatase inhibitors have shown potential as chemopreventive agents","confidence":0.8,"supports":true}
{"relationship_key":"C0593802:TREATS:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":118,"text_span":"Selective estrogen receptor modulators (SERMs) and aromatase inhibitors have shown potential as chemopreventive agents","confidence":0.8,"supports":true}
{"relationship_key":"C0195471:TREATS:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":144,"text_span":"Risk-reducing surgeries, such as bilateral salpingo-oophorectomy (BSO) and mastectomy, significantly lower the risk of breast and ovarian cancer","confidence":0.9,"supports":true}
{"relationship_key":"C0195471:TREATS:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":255,"text_span":"those who underwent risk-reducing BSO had a lower risk of first breast cancer diagnosis compared with those who did not: 7% versus 23% in BRCA2 carriers (HR: 0.36 (95% CI: 0.16 - 0.82)) and 14% versus 20% in BRCA1 carriers (HR: 0.63 (95% CI: 0.41 - 0.96))","confidence":0.9,"supports":true}
{"relationship_key":"C0195471:TREATS:C0029925","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":144,"text_span":"Risk-reducing surgeries, such as bilateral salpingo-oophorectomy (BSO) and mastectomy, significantly lower the risk of breast and ovarian cancer","confidence":0.9,"supports":true}
{"relationship_key":"C0024881:TREATS:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":144,"text_span":"Risk-reducing surgeries, such as bilateral salpingo-oophorectomy (BSO) and mastectomy, significantly lower the risk of breast and ovarian cancer","confidence":0.9,"supports":true}
{"relationship_key":"C0024881:TREATS:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":122,"text_span":"prophylactic bilateral mastectomy (PBM) which has been shown to reduce the incidence of breast cancer by approximately 90%","confidence":0.9,"supports":true}
{"relationship_key":"10324:SUBTYPE_OF:C0360135","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":117,"text_span":"The adjusted HRs were 0.38 (95% CI: 0.27 - 0.55) for BRCA1 carriers and 0.33 (95% CI: 0.22 - 0.50) for BRCA2 carriers","confidence":0.9,"supports":true}
{"relationship_key":"69278:SUBTYPE_OF:C0593802","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":138,"text_span":"exemestane use was associated with significant reduction in invasive breast cancers in all study subgroups (HR: 0.35, 95% CI: 0.18 - 0.70)","confidence":0.9,"supports":true}
{"relationship_key":"10324:TREATS:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":117,"text_span":"The adjusted HRs were 0.38 (95% CI: 0.27 - 0.55) for BRCA1 carriers and 0.33 (95% CI: 0.22 - 0.50) for BRCA2 carriers","confidence":0.9,"supports":true}
{"relationship_key":"69278:TREATS:C0006142","document_id":"PMC12758042","section":null,"start_offset":0,"end_offset":138,"text_span":"exemestane use was associated with significant reduction in invasive breast cancers in all study subgroups (HR: 0.35, 95% CI: 0.18 - 0.70)","confidence":0.9,"supports":true}
{"relationship_key":"canon-f859dc84ec33:ASSOCIATED_WITH:HGNC:9581","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":150,"text_span":"HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration","confidence":0.95,"supports":true}
{"relationship_key":"canon-f859dc84ec33:ASSOCIATED_WITH:HGNC:9581","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":140,"text_span":"HRD-high group exhibited higher mutation frequencies in TP53, RAD51, and SPOP, but fewer mutations in PTEN, ARID1A, PIK3R1, CTNNB1, and CTCF","confidence":0.9,"supports":true}
{"relationship_key":"canon-f859dc84ec33:ASSOCIATED_WITH:canon-06758b86d8c6","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":150,"text_span":"HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration","confidence":0.95,"supports":true}
{"relationship_key":"canon-7ae89029ace8:INDICATES:canon-7f0ef06f39c2","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":162,"text_span":"HRD subtyping independently predicted disease-free survival and showed superior prognostic accuracy (C-index = 0.857) compared to TCGA subtyping (C-index = 0.751)","confidence":0.95,"supports":true}
{"relationship_key":"canon-7ae89029ace8:INDICATES:canon-151f06ab7bf6","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":107,"text_span":"An SVM model incorporating HRD score and immune features achieved an AUC of 0.733 for recurrence prediction","confidence":0.9,"supports":true}
{"relationship_key":"1797886:TREATS:C0476089","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":150,"text_span":"HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration","confidence":0.95,"supports":true}
{"relationship_key":"canon-4ffe0abe2e2f:TREATS:C0476089","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":150,"text_span":"HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration","confidence":0.95,"supports":true}
{"relationship_key":"canon-f859dc84ec33:SUBTYPE_OF:canon-7ae89029ace8","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":150,"text_span":"HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration","confidence":0.95,"supports":true}
{"relationship_key":"canon-c953248f6733:SUBTYPE_OF:canon-7ae89029ace8","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":150,"text_span":"HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration","confidence":0.95,"supports":true}
{"relationship_key":"canon-bc757ed7c03e:SUBTYPE_OF:canon-7ae89029ace8","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":150,"text_span":"HRD-High tumours were associated with advanced FIGO stages, TP53 mutations, higher chromosomal instability, and elevated CD8⁺PD-1⁺ T-cell infiltration","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:4556:ASSOCIATED_WITH:HGNC:9581","document_id":"PMC_ID_NOT_PROVIDED","section":null,"start_offset":0,"end_offset":140,"text_span":"HRD-high group exhibited higher mutation frequencies in TP53, RAD51, and SPOP, but fewer mutations in PTEN, ARID1A, PIK3R1, CTNNB1, and CTCF","confidence":0.9,"supports":true}
{"relationship_key":"C0281477:INDICATES:C0006826","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":216,"text_span":"As a critical component of cancer control, cancer screening assumes a pivotal role in early detection, potentially saving lives by identifying cancers in their early stages or preventing their development altogether.","confidence":0.9,"supports":true}
{"relationship_key":"C1531652:INDICATES:C0242379","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":150,"text_span":"Lung cancer has the highest incidence rate in China, and the National Cancer Center recommends low-dose spiral CT screening for high-risk individuals.","confidence":0.9,"supports":true}
{"relationship_key":"C0009378:INDICATES:C1527249","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":150,"text_span":"Lung cancer has the highest incidence rate in China, and the National Cancer Center recommends low-dose spiral CT screening for high-risk individuals.","confidence":0.9,"supports":true}
{"relationship_key":"C0002210:INDICATES:C0023903","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":150,"text_span":"Lung cancer has the highest incidence rate in China, and the National Cancer Center recommends low-dose spiral CT screening for high-risk individuals.","confidence":0.9,"supports":true}
{"relationship_key":"C0024671:INDICATES:C0006142","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":150,"text_span":"Lung cancer has the highest incidence rate in China, and the National Cancer Center recommends low-dose spiral CT screening for high-risk individuals.","confidence":0.9,"supports":true}
{"relationship_key":"C0021344:INDICATES:C0007847","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":150,"text_span":"Lung cancer has the highest incidence rate in China, and the National Cancer Center recommends low-dose spiral CT screening for high-risk individuals.","confidence":0.9,"supports":true}
{"relationship_key":"canon-ba85687c94b5:ASSOCIATED_WITH:C0281477","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":180,"text_span":"The mean knowledge, attitude, and practice scores were 9.39 ± 3.82 (possible range: 0–20), 31.4 ± 4.06 (possible range: 8–40), and 25.2 ± 7.04 (possible range: 8–40), respectively.","confidence":0.95,"supports":true}
{"relationship_key":"canon-ba85687c94b5:ASSOCIATED_WITH:C0281477","document_id":"PMC12764813","section":null,"start_offset":0,"end_offset":258,"text_span":"Structural equation modeling (SEM) indicated that knowledge directly influenced attitude (β = 0.140, P = 0.003), attitude directly affected practice (β = 0.145, P = 0.002), and knowledge had a substantial and direct impact on practice (β = 0.219, P < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"canon-9b1c03b02728:ASSOCIATED_WITH:HGNC:1100","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":168,"text_span":"BRCA1/2 (e.g. 5296del4 in BRCA1 and 6174delT in BRCA2) mutation was considered as the crucial risk factor in breast cancer, and BRCA2 mutations were more common in MBC.","confidence":0.9,"supports":true}
{"relationship_key":"canon-313eb29f210a:ASSOCIATED_WITH:HGNC:1101","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":168,"text_span":"BRCA1/2 (e.g. 5296del4 in BRCA1 and 6174delT in BRCA2) mutation was considered as the crucial risk factor in breast cancer, and BRCA2 mutations were more common in MBC.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:1100:INCREASES_RISK:C0006142","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":168,"text_span":"BRCA1/2 (e.g. 5296del4 in BRCA1 and 6174delT in BRCA2) mutation was considered as the crucial risk factor in breast cancer, and BRCA2 mutations were more common in MBC.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:1101:INCREASES_RISK:C0006142","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":168,"text_span":"BRCA1/2 (e.g. 5296del4 in BRCA1 and 6174delT in BRCA2) mutation was considered as the crucial risk factor in breast cancer, and BRCA2 mutations were more common in MBC.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:1101:INCREASES_RISK:C0238033","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":168,"text_span":"BRCA1/2 (e.g. 5296del4 in BRCA1 and 6174delT in BRCA2) mutation was considered as the crucial risk factor in breast cancer, and BRCA2 mutations were more common in MBC.","confidence":0.9,"supports":true}
{"relationship_key":"canon-96a95255aff5:ASSOCIATED_WITH:C0238033","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":284,"text_span":"Regarding ethnicity, Mongolian had a higher age-standardized 5-year prevalence rate than Han (3.2[95% CI: 2.5–4.0] vs 2.3[95% CI: 1.7–3.0], P=0.016), but no significant differences existed in incidence rates, survival rates, and risk of all-cause and breast cancer-specific mortality.","confidence":0.95,"supports":true}
{"relationship_key":"canon-53891ec0114e:ASSOCIATED_WITH:C0238033","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":284,"text_span":"Regarding ethnicity, Mongolian had a higher age-standardized 5-year prevalence rate than Han (3.2[95% CI: 2.5–4.0] vs 2.3[95% CI: 1.7–3.0], P=0.016), but no significant differences existed in incidence rates, survival rates, and risk of all-cause and breast cancer-specific mortality.","confidence":0.95,"supports":true}
{"relationship_key":"canon-96a95255aff5:ASSOCIATED_WITH:canon-7030cf6c5cac","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":208,"text_span":"Apart from the result that there was a significantly higher proportion of Mongolian patients who used chemotherapy (38.7% vs 25.0%, P=0.020), no significant disparities were observed in the treatment pattern.","confidence":0.95,"supports":true}
{"relationship_key":"canon-53891ec0114e:ASSOCIATED_WITH:canon-7030cf6c5cac","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":208,"text_span":"Apart from the result that there was a significantly higher proportion of Mongolian patients who used chemotherapy (38.7% vs 25.0%, P=0.020), no significant disparities were observed in the treatment pattern.","confidence":0.95,"supports":true}
{"relationship_key":"C0011847:INCREASES_RISK:C0238033","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":284,"text_span":"Regarding ethnicity, Mongolian had a higher age-standardized 5-year prevalence rate than Han (3.2[95% CI: 2.5–4.0] vs 2.3[95% CI: 1.7–3.0], P=0.016), but no significant differences existed in incidence rates, survival rates, and risk of all-cause and breast cancer-specific mortality.","confidence":0.95,"supports":true}
{"relationship_key":"C0028754:INCREASES_RISK:C0238033","document_id":"PMC_PLACEHOLDER","section":null,"start_offset":0,"end_offset":284,"text_span":"Regarding ethnicity, Mongolian had a higher age-standardized 5-year prevalence rate than Han (3.2[95% CI: 2.5–4.0] vs 2.3[95% CI: 1.7–3.0], P=0.016), but no significant differences existed in incidence rates, survival rates, and risk of all-cause and breast cancer-specific mortality.","confidence":0.95,"supports":true}
{"relationship_key":"canon-1cfde49bb6c7:SUPERIOR_TO:canon-fef60173d53a","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":189,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions (3.5% vs. 1.2%, p = 0.019) than the DNA‐only test.","confidence":0.95,"supports":true}
{"relationship_key":"canon-1cfde49bb6c7:SUPERIOR_TO:canon-fef60173d53a","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":185,"text_span":"Among patients with translocation‐related sarcomas, histology‐specific fusion genes were identified in 77.5% using the dual panel, compared to 40.0% with the DNA‐only panel (p < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"canon-1cfde49bb6c7:DETECTS:canon-9102dcfea369","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":189,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions (3.5% vs. 1.2%, p = 0.019) than the DNA‐only test.","confidence":0.95,"supports":true}
{"relationship_key":"canon-fef60173d53a:DETECTS:canon-9102dcfea369","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":189,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions (3.5% vs. 1.2%, p = 0.019) than the DNA‐only test.","confidence":0.95,"supports":true}
{"relationship_key":"canon-1cfde49bb6c7:ENABLES:2058257","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":172,"text_span":"Molecular targeted therapy was administered more frequently in the GenMineTOP group (10 of 231 patients, 4.3%) than in the F1CDx group (7 of 464 patients, 1.5%) (p = 0.03).","confidence":0.95,"supports":true}
{"relationship_key":"canon-1cfde49bb6c7:DETECTS:canon-a8778749d97d","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":89,"text_span":"GPVs were detected in 21 patients (5.7%) using the tumor–normal matched GenMineTOP panel.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:3508:FUSES_WITH:HGNC:3749","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":189,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions (3.5% vs. 1.2%, p = 0.019) than the DNA‐only test.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11541:FUSES_WITH:HGNC:11335","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":189,"text_span":"The dual DNA–RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p < 0.001) and therapeutically targetable kinase fusions (3.5% vs. 1.2%, p = 0.019) than the DNA‐only test.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:2197:FUSES_WITH:HGNC:8800","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":172,"text_span":"Molecular targeted therapy was administered more frequently in the GenMineTOP group (10 of 231 patients, 4.3%) than in the F1CDx group (7 of 464 patients, 1.5%) (p = 0.03).","confidence":0.95,"supports":true}
{"relationship_key":"282388:TREATS:C0011634","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":172,"text_span":"Molecular targeted therapy was administered more frequently in the GenMineTOP group (10 of 231 patients, 4.3%) than in the F1CDx group (7 of 464 patients, 1.5%) (p = 0.03).","confidence":0.95,"supports":true}
{"relationship_key":"2058257:TREATS:C1261473","document_id":"PMC11729007","section":null,"start_offset":0,"end_offset":172,"text_span":"Molecular targeted therapy was administered more frequently in the GenMineTOP group (10 of 231 patients, 4.3%) than in the F1CDx group (7 of 464 patients, 1.5%) (p = 0.03).","confidence":0.95,"supports":true}
{"relationship_key":"canon-91a7ada96126:TREATS:C3539878","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":113,"text_span":"BGNps exerted potent, concentration-dependent cytotoxicity in MDA-MB-231 cells, with an IC50 value of 184.3 µg/ml","confidence":0.95,"supports":true}
{"relationship_key":"canon-91a7ada96126:TREATS:C3539878","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-91a7ada96126:INDUCES:canon-68bbb055fc8b","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-91a7ada96126:INDUCES:canon-70c845eebb08","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-91a7ada96126:INDUCES:canon-b017119d5a9a","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-91a7ada96126:INDUCES:canon-2e5291a63f63","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-91a7ada96126:UPREGULATES:HGNC:11998","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":143,"text_span":"These effects were associated with marked upregulation of p53 and concurrent downregulation of anti-apoptotic Bcl-2 and mitochondrial ND3 genes","confidence":0.95,"supports":true}
{"relationship_key":"canon-91a7ada96126:DOWNREGULATES:HGNC:990","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":143,"text_span":"These effects were associated with marked upregulation of p53 and concurrent downregulation of anti-apoptotic Bcl-2 and mitochondrial ND3 genes","confidence":0.95,"supports":true}
{"relationship_key":"canon-91a7ada96126:DOWNREGULATES:HGNC:7458","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":143,"text_span":"These effects were associated with marked upregulation of p53 and concurrent downregulation of anti-apoptotic Bcl-2 and mitochondrial ND3 genes","confidence":0.95,"supports":true}
{"relationship_key":"C3539878:CHARACTERIZED_BY_ABSENCE_OF:HGNC:3467","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":237,"text_span":"Triple-negative breast cancer (TNBC) is an aggressive and clinically challenging subtype of breast cancer characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 expression","confidence":0.95,"supports":true}
{"relationship_key":"C3539878:CHARACTERIZED_BY_ABSENCE_OF:HGNC:8910","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":237,"text_span":"Triple-negative breast cancer (TNBC) is an aggressive and clinically challenging subtype of breast cancer characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 expression","confidence":0.95,"supports":true}
{"relationship_key":"C3539878:CHARACTERIZED_BY_ABSENCE_OF:HGNC:3430","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":237,"text_span":"Triple-negative breast cancer (TNBC) is an aggressive and clinically challenging subtype of breast cancer characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 expression","confidence":0.95,"supports":true}
{"relationship_key":"C3539878:SUBTYPE_OF:C0006142","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":237,"text_span":"Triple-negative breast cancer (TNBC) is an aggressive and clinically challenging subtype of breast cancer characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 expression","confidence":0.95,"supports":true}
{"relationship_key":"canon-2e5291a63f63:LEADS_TO:canon-70c845eebb08","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-2e5291a63f63:LEADS_TO:canon-b017119d5a9a","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-b017119d5a9a:LEADS_TO:canon-68bbb055fc8b","document_id":"PMC12780067","section":null,"start_offset":0,"end_offset":245,"text_span":"Treatment with BGNps at the IC50 concentration induced excessive reactive oxygen species (ROS) generation, severe mitochondrial membrane depolarization, extensive genomic DNA damage, and pronounced apoptotic cell death in MDA-MB-231 cancer cells","confidence":0.95,"supports":true}
{"relationship_key":"canon-eab85e28096d:INCREASES_RISK:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":122,"text_span":"The predominant risk factor for PM is asbestos exposure, with approximately 80% of cases linked to prior asbestos contact.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:7371:INDICATES:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":264,"text_span":"Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:7371:INDICATES:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":92,"text_span":"SMRP are the only biomarkers for PM approved by the U.S. Food and Drug Administration (FDA).","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:17635:ASSOCIATED_WITH:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":130,"text_span":"The PD-L1 protein plays a central role in the antitumor immune response. sPD-L1 concentrations were positively correlated with OS.","confidence":0.9,"supports":true}
{"relationship_key":"canon-c1a57a183c23:INDICATES:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":176,"text_span":"miRNAs affect tumor growth, invasion and angiogenesis by binding to mRNAs, thereby influencing the expression of oncogenes and oncogenes and the activity of signaling pathways.","confidence":0.85,"supports":true}
{"relationship_key":"HGNC:31586:ASSOCIATED_WITH:C0812413","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":275,"text_span":"One of the tumorigenic miRNAs associated with PM development is miR-182-5p. miR-182-5p's oncogenic function was first identified in melanoma, where the miRNA promotes tumor migration and invasion by inhibiting the activity of the forkhead box O3 (FOXO3) transcription factor.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:31586:ASSOCIATED_WITH:HGNC:3821","document_id":"PMC12780394","section":null,"start_offset":0,"end_offset":275,"text_span":"One of the tumorigenic miRNAs associated with PM development is miR-182-5p. miR-182-5p's oncogenic function was first identified in melanoma, where the miRNA promotes tumor migration and invasion by inhibiting the activity of the forkhead box O3 (FOXO3) transcription factor.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:12363:ASSOCIATED_WITH:canon-1e861e633b1f","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":167,"text_span":"Non-synonymous TSC2 mutations occurred in 80% of chimpanzees, versus ~7% in human HCC, suggesting a species-specific oncogenic pathway linked to the scirrhous subtype.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:12363:ASSOCIATED_WITH:canon-1e861e633b1f","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":137,"text_span":"TSC2 alterations are present in only 7% of human HCC patients, whereas 80% of chimpanzees with HCC in our study possessed TSC2 mutations.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:12363:INCREASES_RISK:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":167,"text_span":"Non-synonymous TSC2 mutations occurred in 80% of chimpanzees, versus ~7% in human HCC, suggesting a species-specific oncogenic pathway linked to the scirrhous subtype.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:12363:INCREASES_RISK:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":137,"text_span":"TSC2 alterations are present in only 7% of human HCC patients, whereas 80% of chimpanzees with HCC in our study possessed TSC2 mutations.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:12363:REGULATES:canon-65d3bb3a5fa1","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":195,"text_span":"TSC2 is a tumor suppressor gene that encodes the protein Tuberin complexing with Hamartin, the protein encoded by TSC1, and together they inhibit the mammalian target of rapamycin (mTOR) pathway.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11998:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":76,"text_span":"Additional recurrently mutated genes included ARID1A, FAT1–4, TP53, and FGA.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:11998:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":97,"text_span":"Shared alterations across species involved canonical drivers such as TP53, CTNNB1, FAT4, and TTN.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:11110:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":76,"text_span":"Additional recurrently mutated genes included ARID1A, FAT1–4, TP53, and FGA.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:2514:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":97,"text_span":"Shared alterations across species involved canonical drivers such as TP53, CTNNB1, FAT4, and TTN.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:23109:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":76,"text_span":"Additional recurrently mutated genes included ARID1A, FAT1–4, TP53, and FGA.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:23109:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":97,"text_span":"Shared alterations across species involved canonical drivers such as TP53, CTNNB1, FAT4, and TTN.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:12403:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":97,"text_span":"Shared alterations across species involved canonical drivers such as TP53, CTNNB1, FAT4, and TTN.","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:3661:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":76,"text_span":"Additional recurrently mutated genes included ARID1A, FAT1–4, TP53, and FGA.","confidence":0.9,"supports":true}
{"relationship_key":"canon-94b108e66fc8:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":113,"text_span":"Chimpanzee tumors carried significantly higher coding mutation loads (mean 5632 per sample vs. 96–275 in humans).","confidence":0.95,"supports":true}
{"relationship_key":"canon-a981ca9aa26f:ASSOCIATED_WITH:C2239176","document_id":"PMC11729065","section":null,"start_offset":0,"end_offset":113,"text_span":"Chimpanzee tumors carried significantly higher coding mutation loads (mean 5632 per sample vs. 96–275 in humans).","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:1103:ASSOCIATED_WITH:C0597611","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":123,"text_span":"BRD7 has been confirmed to be lowly expressed in nasopharyngeal carcinoma (NPC) tissues and exerts tumour suppressive roles","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:1103:ASSOCIATED_WITH:C0597611","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":160,"text_span":"BRD7 was confirmed to be down-expressed in NPC and acts as a tumour suppressor in NPC by negatively regulating signalling pathways like ERK, Rb/E2F and PI3K/AKT","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:1103:DECREASES:C0027442","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":123,"text_span":"BRD7 has been confirmed to be lowly expressed in nasopharyngeal carcinoma (NPC) tissues and exerts tumour suppressive roles","confidence":0.95,"supports":true}
{"relationship_key":"C1512554:DECREASES:HGNC:1103","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":110,"text_span":"There was hypermethylation modification in BRD7 promoter, which was negatively correlated with BRD7 expression","confidence":0.95,"supports":true}
{"relationship_key":"canon-0473d243f5a7:INCREASES:HGNC:1103","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":165,"text_span":"all five sgRNA-guided CRISPR/dCas9 systems could activate BRD7 and inhibit cell proliferation to varying degrees, among which sgRNA2&sgRNA5 were the most significant","confidence":0.95,"supports":true}
{"relationship_key":"canon-0473d243f5a7:DECREASES:C0596290","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":165,"text_span":"all five sgRNA-guided CRISPR/dCas9 systems could activate BRD7 and inhibit cell proliferation to varying degrees, among which sgRNA2&sgRNA5 were the most significant","confidence":0.95,"supports":true}
{"relationship_key":"canon-0473d243f5a7:DECREASES:C0596290","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":181,"text_span":"both sgRNA2&sgRNA5 could promote the transcriptional activation by reducing its methylation, and inhibit the cell proliferation, migration, invasion and tumour growth in vivo of NPC","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:1103:REGULATES:canon-09fc92c3ba94","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":160,"text_span":"BRD7 was confirmed to be down-expressed in NPC and acts as a tumour suppressor in NPC by negatively regulating signalling pathways like ERK, Rb/E2F and PI3K/AKT","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:1103:REGULATES:canon-583aaf0338ef","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":160,"text_span":"BRD7 was confirmed to be down-expressed in NPC and acts as a tumour suppressor in NPC by negatively regulating signalling pathways like ERK, Rb/E2F and PI3K/AKT","confidence":0.95,"supports":true}
{"relationship_key":"canon-0473d243f5a7:TREATS:C0027442","document_id":"PMC11729088","section":null,"start_offset":0,"end_offset":181,"text_span":"both sgRNA2&sgRNA5 could promote the transcriptional activation by reducing its methylation, and inhibit the cell proliferation, migration, invasion and tumour growth in vivo of NPC","confidence":0.95,"supports":true}
{"relationship_key":"1298331:TREATS:C0006142","document_id":"PMC11729135","section":null,"start_offset":0,"end_offset":167,"text_span":"This strategy has driven the development of sophisticated targeted therapies in cancer, such as PARP inhibitors for patients with BRCA1- or BRCA2-mutated breast cancer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:1100:ASSOCIATED_WITH:C0006142","document_id":"PMC11729135","section":null,"start_offset":0,"end_offset":167,"text_span":"This strategy has driven the development of sophisticated targeted therapies in cancer, such as PARP inhibitors for patients with BRCA1- or BRCA2-mutated breast cancer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:1101:ASSOCIATED_WITH:C0006142","document_id":"PMC11729135","section":null,"start_offset":0,"end_offset":167,"text_span":"This strategy has driven the development of sophisticated targeted therapies in cancer, such as PARP inhibitors for patients with BRCA1- or BRCA2-mutated breast cancer","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:3527:ASSOCIATED_WITH:C0018939","document_id":"PMC11729135","section":null,"start_offset":0,"end_offset":256,"text_span":"Among different candidates, we identified the essentiality of EZH2 specifically in hematological cancer cell lines in all iMR models build on TRRUST. Interestingly, this gene has been previously identified as a drug target of different hematological tumors","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:3527:INTERACTS_WITH:HGNC:6204","document_id":"PMC11729135","section":null,"start_offset":0,"end_offset":215,"text_span":"the lethality of EZH2 inhibition is mediated by the following gMIS: {EZH2−, JUN−, RELA+}, hypothesizing a higher impact in cellular proliferation when the expression of JUN is down-regulated and RELA is up-regulated","confidence":0.85,"supports":true}
{"relationship_key":"HGNC:3527:INTERACTS_WITH:HGNC:9955","document_id":"PMC11729135","section":null,"start_offset":0,"end_offset":215,"text_span":"the lethality of EZH2 inhibition is mediated by the following gMIS: {EZH2−, JUN−, RELA+}, hypothesizing a higher impact in cellular proliferation when the expression of JUN is down-regulated and RELA is up-regulated","confidence":0.85,"supports":true}
{"relationship_key":"HGNC:3071:INTERACTS_WITH:HGNC:4096","document_id":"PMC11729135","section":null,"start_offset":0,"end_offset":183,"text_span":"consider the SDL interaction formed by the following two genes: {DUSP4+; GADD45B−}, where the high expression of DUSP4 and the low expression of GADD45B inhibit cellular proliferation","confidence":0.8,"supports":true}
{"relationship_key":"HGNC:1775:INTERACTS_WITH:HGNC:10840","document_id":"PMC11729135","section":null,"start_offset":0,"end_offset":186,"text_span":"we also examined the following tumor suppressor gene complex comprising two genes: {CDK5RAP3+; SHC1+}, where the high expression of both genes is required to block cellular proliferation","confidence":0.8,"supports":true}
{"relationship_key":"canon-3600fa46435b:ASSOCIATED_WITH:C0006826","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":197,"text_span":"The manipulation of ferroptosis has become an attractive area of cancer research, as both the promotion and inhibition of this form of cell death have been seen to positively affect cancer outcomes","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:11998:REGULATES:HGNC:11059","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":202,"text_span":"TP53 is the most frequently mutated tumor-suppressor gene and can play an important role in the promotion of ferroptosis in cancer. It downregulates SLC7A11 expression, a key component of the xCT system","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11998:PROMOTES:canon-3600fa46435b","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":202,"text_span":"TP53 is the most frequently mutated tumor-suppressor gene and can play an important role in the promotion of ferroptosis in cancer. It downregulates SLC7A11 expression, a key component of the xCT system","confidence":0.95,"supports":true}
{"relationship_key":"1797886:INHIBITS:HGNC:11059","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":204,"text_span":"Erastin acts through the inhibition of the xCT antiporter composed of both SLC7A11 and SLC3A2. Inhibition of this antiporter leads to decreased intracellular cystine uptake and subsequent depletion of GSH","confidence":0.95,"supports":true}
{"relationship_key":"1797886:INDUCES:canon-3600fa46435b","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":204,"text_span":"Erastin acts through the inhibition of the xCT antiporter composed of both SLC7A11 and SLC3A2. Inhibition of this antiporter leads to decreased intracellular cystine uptake and subsequent depletion of GSH","confidence":0.95,"supports":true}
{"relationship_key":"canon-8d118d3f09b7:INHIBITS:HGNC:4555","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":102,"text_span":"RSL3 is another induction molecule that directly inhibits GPX4 by bypassing the need for GSH depletion","confidence":0.95,"supports":true}
{"relationship_key":"canon-8d118d3f09b7:INDUCES:canon-3600fa46435b","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":102,"text_span":"RSL3 is another induction molecule that directly inhibits GPX4 by bypassing the need for GSH depletion","confidence":0.95,"supports":true}
{"relationship_key":"608804:TREATS:C2239176","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":134,"text_span":"An HCC study has shown that sorafenib enhances ferroptosis through the inhibition of SLC7A11 and subsequent decrease in cystine uptake","confidence":0.9,"supports":true}
{"relationship_key":"608804:INHIBITS:HGNC:11059","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":134,"text_span":"An HCC study has shown that sorafenib enhances ferroptosis through the inhibition of SLC7A11 and subsequent decrease in cystine uptake","confidence":0.9,"supports":true}
{"relationship_key":"canon-1cf956e15edc:REQUIRED_FOR:canon-3600fa46435b","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":193,"text_span":"Ferroptosis is an iron-dependent form of programmed cell death that is driven by the accumulation of reactive oxygen species (ROS), leading to the formation of membrane-damaging lipid peroxides","confidence":0.95,"supports":true}
{"relationship_key":"canon-bdf16ee1962c:CAUSES:canon-edb6251f8e67","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":193,"text_span":"Ferroptosis is an iron-dependent form of programmed cell death that is driven by the accumulation of reactive oxygen species (ROS), leading to the formation of membrane-damaging lipid peroxides","confidence":0.95,"supports":true}
{"relationship_key":"canon-edb6251f8e67:LEADS_TO:canon-3600fa46435b","document_id":"PMC12784773","section":null,"start_offset":0,"end_offset":193,"text_span":"Ferroptosis is an iron-dependent form of programmed cell death that is driven by the accumulation of reactive oxygen species (ROS), leading to the formation of membrane-damaging lipid peroxides","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:3229:INCREASES_EXPRESSION_OF:HGNC:11191","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":95,"text_span":"EGF supplement significantly upregulates both the protein and mRNA expression of the Sox11 gene","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11364:REGULATES:HGNC:11191","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":111,"text_span":"STAT3 bound to the Sox11 gene promoter and transcriptionally upregulated the expression of Sox11 in HNSCC cells","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:PROMOTES:canon-90db8977a401","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":182,"text_span":"Knockdown of SOX11 significantly downregulated the expression of EMT-related genes, including EMT-TFs, vimentin, fibronectin, and N-cadherin, but significantly upregulated E-cadherin","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:PROMOTES:canon-90db8977a401","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:12428","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":68,"text_span":"SOX11 bound to the promoter region of the Twist1 gene in HNSCC cells","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:12428","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":82,"text_span":"SOX11 was found to promote HNSCC tumor growth and the expression of TWIST1 in vivo","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:12692","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":182,"text_span":"Knockdown of SOX11 significantly downregulated the expression of EMT-related genes, including EMT-TFs, vimentin, fibronectin, and N-cadherin, but significantly upregulated E-cadherin","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:12692","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:3778","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":182,"text_span":"Knockdown of SOX11 significantly downregulated the expression of EMT-related genes, including EMT-TFs, vimentin, fibronectin, and N-cadherin, but significantly upregulated E-cadherin","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:3778","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:1759","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":182,"text_span":"Knockdown of SOX11 significantly downregulated the expression of EMT-related genes, including EMT-TFs, vimentin, fibronectin, and N-cadherin, but significantly upregulated E-cadherin","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:INCREASES_EXPRESSION_OF:HGNC:1759","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:DECREASES_EXPRESSION_OF:HGNC:1748","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":182,"text_span":"Knockdown of SOX11 significantly downregulated the expression of EMT-related genes, including EMT-TFs, vimentin, fibronectin, and N-cadherin, but significantly upregulated E-cadherin","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:DECREASES_EXPRESSION_OF:HGNC:1748","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":153,"text_span":"SOX11 overexpression significantly inhibited E-cadherin gene expression but induced the gene expression of N-cadherin, vimentin, fibronectin, and EMT-TFs","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11191:ASSOCIATED_WITH:C1168401","document_id":"extracted_from_title","section":null,"start_offset":0,"end_offset":82,"text_span":"SOX11 was found to promote HNSCC tumor growth and the expression of TWIST1 in vivo","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11393:ASSOCIATED_WITH:C0019204","document_id":"PMC12785631","section":null,"start_offset":0,"end_offset":190,"text_span":"AURKA level was significantly increased in both test groups (p < 0.001). At the protein level, AURKA was significantly higher in both cancer groups compared to the control group (p < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11393:ASSOCIATED_WITH:C0019204","document_id":"PMC12785631","section":null,"start_offset":0,"end_offset":190,"text_span":"AURKA level was significantly increased in both test groups (p < 0.001). At the protein level, AURKA was significantly higher in both cancer groups compared to the control group (p < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11393:PHOSPHORYLATES:HGNC:9077","document_id":"PMC12785631","section":null,"start_offset":0,"end_offset":110,"text_span":"AURKA directly phosphorylates the Thr210 residue within the PLK1 kinase domain, initiating mitotic progression","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11393:PHOSPHORYLATES:HGNC:11998","document_id":"PMC12785631","section":null,"start_offset":0,"end_offset":198,"text_span":"Overexpression of AURKA has been shown to destabilize p53 through Ser315 phosphorylation, leading to loss of function, centrosome amplification, chromosomal instability, and oncogenic transformation","confidence":0.95,"supports":true}
{"relationship_key":"1298331:SYNERGISTIC_WITH:608406","document_id":"PMC12785631","section":null,"start_offset":0,"end_offset":117,"text_span":"experimental studies have demonstrated that MLN8237 exhibits a strong synergistic effect with Sorafenib in HCC models","confidence":0.9,"supports":true}
{"relationship_key":"1298331:TREATS:C0019204","document_id":"PMC12785631","section":null,"start_offset":0,"end_offset":117,"text_span":"experimental studies have demonstrated that MLN8237 exhibits a strong synergistic effect with Sorafenib in HCC models","confidence":0.9,"supports":true}
{"relationship_key":"C0019204:SUBTYPE_OF:C0019204","document_id":"PMC12785631","section":null,"start_offset":0,"end_offset":190,"text_span":"AURKA level was significantly increased in both test groups (p < 0.001). At the protein level, AURKA was significantly higher in both cancer groups compared to the control group (p < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"C0019204:SUBTYPE_OF:C0019204","document_id":"PMC12785631","section":null,"start_offset":0,"end_offset":190,"text_span":"AURKA level was significantly increased in both test groups (p < 0.001). At the protein level, AURKA was significantly higher in both cancer groups compared to the control group (p < 0.001).","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11998:INDICATES:C0085390","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":120,"text_span":"When TP53 PVs/LPVs are identified in a comprehensive germline panel, this raises concern for Li–Fraumeni syndrome (LFS).","confidence":0.95,"supports":true}
{"relationship_key":"C0085390:INCREASES_RISK:C0006142","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":212,"text_span":"LFS is a hereditary cancer syndrome that is associated with increased risk for multiple cancers, including, but not limited to, breast cancer, sarcoma, central nervous system tumors, and adrenocortical carcinoma.","confidence":0.95,"supports":true}
{"relationship_key":"C0085390:INCREASES_RISK:C0006142","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":129,"text_span":"The breast cancer risk for women with LFS/germline TP53 LPVs/PVs is 80%–90%, with most breast cancers occurring at a younger age.","confidence":0.95,"supports":true}
{"relationship_key":"C0085390:INCREASES_RISK:C1261473","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":212,"text_span":"LFS is a hereditary cancer syndrome that is associated with increased risk for multiple cancers, including, but not limited to, breast cancer, sarcoma, central nervous system tumors, and adrenocortical carcinoma.","confidence":0.95,"supports":true}
{"relationship_key":"C0085390:INCREASES_RISK:C0006118","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":212,"text_span":"LFS is a hereditary cancer syndrome that is associated with increased risk for multiple cancers, including, but not limited to, breast cancer, sarcoma, central nervous system tumors, and adrenocortical carcinoma.","confidence":0.95,"supports":true}
{"relationship_key":"C0085390:INCREASES_RISK:C0001623","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":212,"text_span":"LFS is a hereditary cancer syndrome that is associated with increased risk for multiple cancers, including, but not limited to, breast cancer, sarcoma, central nervous system tumors, and adrenocortical carcinoma.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:11998:ASSOCIATED_WITH:C0206650","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":82,"text_span":"Phyllodes tumors have been associated with germline TP53, BRCA1, and RB1 PVs/LPVs.","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:1100:ASSOCIATED_WITH:C0206650","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":82,"text_span":"Phyllodes tumors have been associated with germline TP53, BRCA1, and RB1 PVs/LPVs.","confidence":0.95,"supports":true}
{"relationship_key":"C0085390:INCREASES_RISK:C1522449","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":159,"text_span":"It has been demonstrated that patients with LFS who receive radiation therapy have an increased risk of radiation‐related malignancies within irradiated areas.","confidence":0.95,"supports":true}
{"relationship_key":"C0024881:TREATS:C0006142","document_id":"PMC12788344","section":null,"start_offset":0,"end_offset":129,"text_span":"The breast cancer risk for women with LFS/germline TP53 LPVs/PVs is 80%–90%, with most breast cancers occurring at a younger age.","confidence":0.95,"supports":true}
{"relationship_key":"202477:INCREASES_RISK:C0010481","document_id":"PMC2386281","section":null,"start_offset":0,"end_offset":264,"text_span":"After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma.","confidence":0.95,"supports":true}
{"relationship_key":"C0750952:ASSOCIATED_WITH:C0010481","document_id":"PMC2386281","section":null,"start_offset":0,"end_offset":264,"text_span":"After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma.","confidence":0.95,"supports":true}
{"relationship_key":"canon-e4645c514a71:INDICATES:C0010481","document_id":"PMC2386281","section":null,"start_offset":0,"end_offset":174,"text_span":"We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test).","confidence":0.95,"supports":true}
{"relationship_key":"canon-f2291b801bc0:INDICATES:C0010481","document_id":"PMC2386281","section":null,"start_offset":0,"end_offset":174,"text_span":"We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test).","confidence":0.95,"supports":true}
{"relationship_key":"canon-55bf485867ed:INDICATES:C0010481","document_id":"PMC2386281","section":null,"start_offset":0,"end_offset":174,"text_span":"We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test).","confidence":0.95,"supports":true}
{"relationship_key":"canon-a83b8b7c9801:INDICATES:C0010481","document_id":"PMC2386281","section":null,"start_offset":0,"end_offset":174,"text_span":"We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test).","confidence":0.95,"supports":true}
{"relationship_key":"canon-73fb9c68b5d9:INDICATES:C0010481","document_id":"PMC2386281","section":null,"start_offset":0,"end_offset":196,"text_span":"We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test.","confidence":0.95,"supports":true}
{"relationship_key":"canon-258393916aec:INDICATES:C0010481","document_id":"PMC2386281","section":null,"start_offset":0,"end_offset":196,"text_span":"We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test.","confidence":0.95,"supports":true}
{"relationship_key":"9778:TREATS:C0282488","document_id":"PMC3622825","section":null,"start_offset":0,"end_offset":248,"text_span":"The duration of excitatory responses to noxious UBD during acute colonic inflammation (3 days post-TNBS) was significantly shortened in the group with RTX pretreatment (25.37±.5 s, n=49) when compared to the control group (35.1±4.2 s, n=43, p≤0.05)","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:16802:ASSOCIATED_WITH:C0021368","document_id":"PMC3622825","section":null,"start_offset":0,"end_offset":248,"text_span":"The duration of excitatory responses to noxious UBD during acute colonic inflammation (3 days post-TNBS) was significantly shortened in the group with RTX pretreatment (25.37±.5 s, n=49) when compared to the control group (35.1±4.2 s, n=43, p≤0.05)","confidence":0.95,"supports":true}
{"relationship_key":"HGNC:16802:ASSOCIATED_WITH:canon-b3f66e0dc7fc","document_id":"PMC3622825","section":null,"start_offset":0,"end_offset":248,"text_span":"The duration of excitatory responses to noxious UBD during acute colonic inflammation (3 days post-TNBS) was significantly shortened in the group with RTX pretreatment (25.37±.5 s, n=49) when compared to the control group (35.1±4.2 s, n=43, p≤0.05)","confidence":0.95,"supports":true}
{"relationship_key":"canon-2a45a1127881:CAUSES:C0009319","document_id":"PMC3622825","section":null,"start_offset":0,"end_offset":172,"text_span":"Acute colitis (TNBS, 3 days), however, had no effect on the expression of TRPV1 in the urinary bladder, but increased the level of the protein in the distal colon by 2-fold","confidence":0.9,"supports":true}
{"relationship_key":"9778:DECREASES:HGNC:16802","document_id":"PMC3622825","section":null,"start_offset":0,"end_offset":188,"text_span":"Western blotting results provide evidence for a significant decrease in TRPV1 expression after intravesical treatment with RTX in the urothelium and DSM without changes in the distal colon","confidence":0.9,"supports":true}
{"relationship_key":"C0009319:INCREASES:HGNC:16802","document_id":"PMC3622825","section":null,"start_offset":0,"end_offset":172,"text_span":"Acute colitis (TNBS, 3 days), however, had no effect on the expression of TRPV1 in the urinary bladder, but increased the level of the protein in the distal colon by 2-fold","confidence":0.9,"supports":true}
{"relationship_key":"canon-b3f66e0dc7fc:ASSOCIATED_WITH:C0282488","document_id":"PMC3622825","section":null,"start_offset":0,"end_offset":248,"text_span":"The duration of excitatory responses to noxious UBD during acute colonic inflammation (3 days post-TNBS) was significantly shortened in the group with RTX pretreatment (25.37±.5 s, n=49) when compared to the control group (35.1±4.2 s, n=43, p≤0.05)","confidence":0.95,"supports":true}
{"relationship_key":"9778:MODULATES:canon-6ac7084dcf6b","document_id":"PMC3622825","section":null,"start_offset":0,"end_offset":248,"text_span":"The duration of excitatory responses to noxious UBD during acute colonic inflammation (3 days post-TNBS) was significantly shortened in the group with RTX pretreatment (25.37±.5 s, n=49) when compared to the control group (35.1±4.2 s, n=43, p≤0.05)","confidence":0.95,"supports":true}
{"relationship_key":"9778:MODULATES:canon-6ac7084dcf6b","document_id":"PMC3622825","section":null,"start_offset":0,"end_offset":196,"text_span":"Large somatic fields were found more frequently for viscerosomatic spinal neurons in rats pretreated with RTX in comparison to somatic fields mapped in vehicle treated animals (58% vs 23%, p≤0.01)","confidence":0.9,"supports":true}
{"relationship_key":"C0078939:INCREASES_RISK:C0002395","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":162,"text_span":"Amyloid-β oligomers trigger Alzheimer disease pathophysiology via the interaction of cellular prion protein (PrPC) with metabotropic glutamate receptor 5 (mGluR5)","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:9449:ASSOCIATED_WITH:HGNC:4597","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":162,"text_span":"Amyloid-β oligomers trigger Alzheimer disease pathophysiology via the interaction of cellular prion protein (PrPC) with metabotropic glutamate receptor 5 (mGluR5)","confidence":0.9,"supports":true}
{"relationship_key":"HGNC:9449:ASSOCIATED_WITH:HGNC:4597","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":85,"text_span":"PrPC region 91–153 interacts preferentially with the activated conformation of mGluR5","confidence":0.9,"supports":true}
{"relationship_key":"canon-eda494411cbd:ASSOCIATED_WITH:HGNC:4597","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":85,"text_span":"PrPC region 91–153 interacts preferentially with the activated conformation of mGluR5","confidence":0.9,"supports":true}
{"relationship_key":"canon-ff711844f576:TREATS:C0002395","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":125,"text_span":"Antibodies against PrPC region 91–153 and agonist/antagonist-driven mGluR5 conformations regulate the PrPC-mGluR5 interaction","confidence":0.9,"supports":true}
{"relationship_key":"canon-ff711844f576:TREATS:C0002395","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":133,"text_span":"These findings have therapeutic implications for Alzheimer disease by identifying compounds that modulate the PrPC-mGluR5 interaction","confidence":0.9,"supports":true}
{"relationship_key":"canon-6118d1b43527:TREATS:C0002395","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":125,"text_span":"Antibodies against PrPC region 91–153 and agonist/antagonist-driven mGluR5 conformations regulate the PrPC-mGluR5 interaction","confidence":0.9,"supports":true}
{"relationship_key":"canon-6118d1b43527:TREATS:C0002395","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":133,"text_span":"These findings have therapeutic implications for Alzheimer disease by identifying compounds that modulate the PrPC-mGluR5 interaction","confidence":0.9,"supports":true}
{"relationship_key":"canon-ddc8557affc4:TREATS:C0002395","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":125,"text_span":"Antibodies against PrPC region 91–153 and agonist/antagonist-driven mGluR5 conformations regulate the PrPC-mGluR5 interaction","confidence":0.9,"supports":true}
{"relationship_key":"canon-ddc8557affc4:TREATS:C0002395","document_id":"PMC4192497","section":null,"start_offset":0,"end_offset":133,"text_span":"These findings have therapeutic implications for Alzheimer disease by identifying compounds that modulate the PrPC-mGluR5 interaction","confidence":0.9,"supports":true}
{"relationship_key":"C0032000:CAUSES:C0010481","document_id":"PMC4374115","section":null,"start_offset":0,"end_offset":186,"text_span":"Cushing's disease is a rare disorder characterized by overproduction of ACTH from a pituitary adenoma leading to hypercortisolemia that in turn leads to increased morbidity and mortality","confidence":0.95,"supports":true}
{"relationship_key":"C0010481:CAUSES:C0020626","document_id":"PMC4374115","section":null,"start_offset":0,"end_offset":186,"text_span":"Cushing's disease is a rare disorder characterized by overproduction of ACTH from a pituitary adenoma leading to hypercortisolemia that in turn leads to increased morbidity and mortality","confidence":0.95,"supports":true}
{"relationship_key":"C0010481:INCREASES_RISK:C0007222","document_id":"PMC4374115","section":null,"start_offset":0,"end_offset":90,"text_span":"increased cardiovascular risk may persist despite long-term remission of hypercortisolemia","confidence":0.9,"supports":true}
{"relationship_key":"C0010481:ASSOCIATED_WITH:C0020538","document_id":"PMC4374115","section":null,"start_offset":0,"end_offset":45,"text_span":"Hypertension occurs in 55–85 % of CD patients","confidence":0.95,"supports":true}
{"relationship_key":"C0010481:ASSOCIATED_WITH:C0011849","document_id":"PMC4374115","section":null,"start_offset":0,"end_offset":108,"text_span":"The prevalence of overt diabetes mellitus is 20–47 % and that of impaired glucose tolerance is 21–64 % in CD","confidence":0.95,"supports":true}
{"relationship_key":"C0010481:ASSOCIATED_WITH:C0271650","document_id":"PMC4374115","section":null,"start_offset":0,"end_offset":108,"text_span":"The prevalence of overt diabetes mellitus is 20–47 % and that of impaired glucose tolerance is 21–64 % in CD","confidence":0.95,"supports":true}
{"relationship_key":"C0010481:ASSOCIATED_WITH:C0242339","document_id":"PMC4374115","section":null,"start_offset":0,"end_offset":51,"text_span":"Lipid abnormalities occur in 38–71 % of CD patients","confidence":0.95,"supports":true}
{"relationship_key":"C0010481:ASSOCIATED_WITH:C0029456","document_id":"PMC4374115","section":null,"start_offset":0,"end_offset":99,"text_span":"The prevalence of fractures and osteoporosis has been reported to be 15–50 and 38–50 % respectively","confidence":0.95,"supports":true}
{"relationship_key":"C0010481:ASSOCIATED_WITH:C0016658","document_id":"PMC4374115","section":null,"start_offset":0,"end_offset":99,"text_span":"The prevalence of fractures and osteoporosis has been reported to be 15–50 and 38–50 % respectively","confidence":0.95,"supports":true}
{"relationship_key":"C0010481:ASSOCIATED_WITH:C0011570","document_id":"PMC4374115","section":null,"start_offset":0,"end_offset":65,"text_span":"Most (54–85 %) patients with CD have some psychiatric disturbance","confidence":0.95,"supports":true}
{"relationship_key":"C0010481:ASSOCIATED_WITH:C0022650","document_id":"PMC4374115","section":null,"start_offset":0,"end_offset":57,"text_span":"Nephrolithiasis is reported in 50 % of active CD patients","confidence":0.95,"supports":true}
{"relationship_key":"canon-e768bf6d3d0d:TREATS:C0010481","document_id":"PMC4374115","section":null,"start_offset":0,"end_offset":186,"text_span":"Cushing's disease is a rare disorder characterized by overproduction of ACTH from a pituitary adenoma leading to hypercortisolemia that in turn leads to increased morbidity and mortality","confidence":0.95,"supports":true}
{"relationship_key":"canon-c763b58b6e8d:HAS_PROPERTY:canon-6c01ef80fe45","document_id":"PMC4398279","section":null,"start_offset":0,"end_offset":185,"text_span":"This matrix not only yields bacterial phenotypes that can be different from their planktonic counterparts, but also offers physical protection against mechanical and chemical challenges","confidence":0.9,"supports":true}
{"relationship_key":"canon-7b48ad60f66c:PROVIDES:canon-93ed6f37f3f0","document_id":"PMC4398279","section":null,"start_offset":0,"end_offset":185,"text_span":"This matrix not only yields bacterial phenotypes that can be different from their planktonic counterparts, but also offers physical protection against mechanical and chemical challenges","confidence":0.9,"supports":true}
{"relationship_key":"canon-6c01ef80fe45:AFFECTS:canon-afd141c72fb2","document_id":"PMC4398279","section":null,"start_offset":0,"end_offset":162,"text_span":"Penetration of chlorhexidine into oral biofilms increased with increasing relative importance of the slow and decreasing importance of the fast relaxation element","confidence":0.9,"supports":true}
{"relationship_key":"2582:PENETRATES:canon-c763b58b6e8d","document_id":"PMC4398279","section":null,"start_offset":0,"end_offset":162,"text_span":"Penetration of chlorhexidine into oral biofilms increased with increasing relative importance of the slow and decreasing importance of the fast relaxation element","confidence":0.9,"supports":true}
{"relationship_key":"canon-420da2d5f051:ENHANCES:4603","document_id":"PMC4398279","section":null,"start_offset":0,"end_offset":156,"text_span":"Gentamicin has been shown to have enhanced killing in P. aeruginosa and Escherichia coli biofilms in vitro and in vivo in rabbits after ultrasound treatment","confidence":0.9,"supports":true}
{"relationship_key":"canon-c763b58b6e8d:CAUSES:canon-ed0e7191840b","document_id":"PMC4398279","section":null,"start_offset":0,"end_offset":127,"text_span":"In the medical arena, it is currently estimated that over 60% of all human infections treated by physicians are due to biofilms","confidence":0.9,"supports":true}
{"relationship_key":"canon-6c01ef80fe45:ENABLES:canon-379d9897d29e","document_id":"PMC4398279","section":null,"start_offset":0,"end_offset":174,"text_span":"The viscoelasticity of biofilms allows these streamers the possibility to extend and therewith organisms residing in the biofilm gain time to adapt to the new flow conditions","confidence":0.8,"supports":true}
{"relationship_key":"1364430:TREATS:C0004238","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":259,"text_span":"Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin.","confidence":0.95,"supports":true}
{"relationship_key":"1364430:PREVENTS:C0038454","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":259,"text_span":"Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin.","confidence":0.95,"supports":true}
{"relationship_key":"1364430:PREVENTS:C0013922","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":259,"text_span":"Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin.","confidence":0.95,"supports":true}
{"relationship_key":"1364430:REDUCES_RISK:C0019080","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":259,"text_span":"Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin.","confidence":0.95,"supports":true}
{"relationship_key":"1364430:REDUCES_RISK:C0019080","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":188,"text_span":"ARISTOTLE revealed a 21 % relative risk reduction in the primary efficacy endpoint (stroke or systemic embolism) and a 31 % relative risk reduction in the safety endpoint (major bleeding).","confidence":0.95,"supports":true}
{"relationship_key":"1364430:SUPERIOR_TO:703","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":260,"text_span":"The study revealed that apixaban is cost-effective compared with warfarin using a willingness to pay threshold ranging from 1 to 3 per capita Gross Domestic Product (11558 – 34664 USD) with an incremental cost-effectiveness ratio of 786.08 USD per QALY gained.","confidence":0.95,"supports":true}
{"relationship_key":"1364430:SUPERIOR_TO:703","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":385,"text_span":"In a VKA suitable cohort of 1000 patients with NVAF, compared with warfarin, the use of apixaban resulted in 24 fewer strokes (including first and recurrent ischemic and hemorrhagic) or systemic embolism, 41 fewer major bleeding events (including first and recurrent hemorrhagic stroke, other intracranial hemorrhage and other major bleeds), and 26 fewer cardiovascular-related deaths.","confidence":0.95,"supports":true}
{"relationship_key":"C0004238:INCREASES_RISK:C0038454","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":188,"text_span":"ARISTOTLE revealed a 21 % relative risk reduction in the primary efficacy endpoint (stroke or systemic embolism) and a 31 % relative risk reduction in the safety endpoint (major bleeding).","confidence":0.95,"supports":true}
{"relationship_key":"C0004238:INCREASES_RISK:C0013922","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":188,"text_span":"ARISTOTLE revealed a 21 % relative risk reduction in the primary efficacy endpoint (stroke or systemic embolism) and a 31 % relative risk reduction in the safety endpoint (major bleeding).","confidence":0.95,"supports":true}
{"relationship_key":"canon-0cec9b122669:PREDICTS_RISK:C0038454","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":188,"text_span":"ARISTOTLE revealed a 21 % relative risk reduction in the primary efficacy endpoint (stroke or systemic embolism) and a 31 % relative risk reduction in the safety endpoint (major bleeding).","confidence":0.95,"supports":true}
{"relationship_key":"canon-c746f09de9d1:PREDICTS_RISK:C0038454","document_id":"PMC4480270","section":null,"start_offset":0,"end_offset":188,"text_span":"ARISTOTLE revealed a 21 % relative risk reduction in the primary efficacy endpoint (stroke or systemic embolism) and a 31 % relative risk reduction in the safety endpoint (major bleeding).","confidence":0.95,"supports":true}
{"relationship_key":"C0201516:INDICATES:C0001623","document_id":"PMC4880116","section":null,"start_offset":0,"end_offset":115,"text_span":"We recommend a short corticotropin test (250 μg) as the 'gold standard' diagnostic tool to establish the diagnosis.","confidence":0.95,"supports":true}
{"relationship_key":"4316:TREATS:C0001623","document_id":"PMC4880116","section":null,"start_offset":0,"end_offset":181,"text_span":"We recommend once-daily fludrocortisone (median, 0.1 mg) and hydrocortisone (15–25 mg/d) or cortisone acetate replacement (20–35 mg/d) applied in two to three daily doses in adults.","confidence":0.95,"supports":true}
{"relationship_key":"5492:TREATS:C0001623","document_id":"PMC4880116","section":null,"start_offset":0,"end_offset":181,"text_span":"We recommend once-daily fludrocortisone (median, 0.1 mg) and hydrocortisone (15–25 mg/d) or cortisone acetate replacement (20–35 mg/d) applied in two to three daily doses in adults.","confidence":0.95,"supports":true}
{"relationship_key":"2670:TREATS:C0001623","document_id":"PMC4880116","section":null,"start_offset":0,"end_offset":181,"text_span":"We recommend once-daily fludrocortisone (median, 0.1 mg) and hydrocortisone (15–25 mg/d) or cortisone acetate replacement (20–35 mg/d) applied in two to three daily doses in adults.","confidence":0.95,"supports":true}
{"relationship_key":"C0027497:INDICATES:C0001623","document_id":"PMC4880116","section":null,"start_offset":0,"end_offset":105,"text_span":"This is also recommended for pregnant women with unexplained persistent nausea, fatigue, and hypotension.","confidence":0.9,"supports":true}
{"relationship_key":"C0015672:INDICATES:C0001623","document_id":"PMC4880116","section":null,"start_offset":0,"end_offset":105,"text_span":"This is also recommended for pregnant women with unexplained persistent nausea, fatigue, and hypotension.","confidence":0.9,"supports":true}
{"relationship_key":"C0020649:INDICATES:C0001623","document_id":"PMC4880116","section":null,"start_offset":0,"end_offset":105,"text_span":"This is also recommended for pregnant women with unexplained persistent nausea, fatigue, and hypotension.","confidence":0.9,"supports":true}
{"relationship_key":"C0443286:INDICATES:C0001623","document_id":"PMC4880116","section":null,"start_offset":0,"end_offset":108,"text_span":"Diagnosis of the underlying cause should include a validated assay of autoantibodies against 21-hydroxylase.","confidence":0.95,"supports":true}
{"relationship_key":"C0001623:ASSOCIATED_WITH:C0040128","document_id":"PMC4880116","section":null,"start_offset":0,"end_offset":181,"text_span":"We recommend once-daily fludrocortisone (median, 0.1 mg) and hydrocortisone (15–25 mg/d) or cortisone acetate replacement (20–35 mg/d) applied in two to three daily doses in adults.","confidence":0.95,"supports":true}
{"relationship_key":"canon-ce788ec64ea9:TREATS:C0037929","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":248,"text_span":"Following BMSC transplantation, motoneurons extent of shrinkage were reduced and the animals' Basso, Beattie, and Bresnahan (BBB) locomotion scale scores were significantly higher at 21 and 28 days after injury when compared with the injured group.","confidence":0.95,"supports":true}
{"relationship_key":"canon-ce788ec64ea9:TREATS:C0037929","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":132,"text_span":"At days 21 and 28 after injury, the hSCI + BMSCs group had significantly higher BBB scores than did the hSCI alone group (p < 0.05).","confidence":0.95,"supports":true}
{"relationship_key":"canon-ce788ec64ea9:INCREASES:canon-8daec062ba67","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":248,"text_span":"Following BMSC transplantation, motoneurons extent of shrinkage were reduced and the animals' Basso, Beattie, and Bresnahan (BBB) locomotion scale scores were significantly higher at 21 and 28 days after injury when compared with the injured group.","confidence":0.95,"supports":true}
{"relationship_key":"canon-ce788ec64ea9:INCREASES:canon-8daec062ba67","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":132,"text_span":"At days 21 and 28 after injury, the hSCI + BMSCs group had significantly higher BBB scores than did the hSCI alone group (p < 0.05).","confidence":0.95,"supports":true}
{"relationship_key":"canon-ce788ec64ea9:DECREASES:canon-09086e310bb1","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":138,"text_span":"BMSC transplantation greatly reduced the density of GFAP staining, suggesting that transplanted BMSCs inhibited scar formation (p < 0.05).","confidence":0.95,"supports":true}
{"relationship_key":"canon-ce788ec64ea9:INCREASES:HGNC:2169","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":193,"text_span":"Corresponding elevations in the expression of STAT3 and CNTF mRNA were observed in the hSCI + BMSCs group, and the levels were not significantly different from those observed in the sham group.","confidence":0.95,"supports":true}
{"relationship_key":"canon-ce788ec64ea9:INCREASES:HGNC:2169","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":126,"text_span":"The CNTF and STAT3 mRNA levels in the hSCI + BMSC group were markedly upregulated (p < 0.05) compared to the hSCI alone group.","confidence":0.95,"supports":true}
{"relationship_key":"canon-ce788ec64ea9:INCREASES:HGNC:11364","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":193,"text_span":"Corresponding elevations in the expression of STAT3 and CNTF mRNA were observed in the hSCI + BMSCs group, and the levels were not significantly different from those observed in the sham group.","confidence":0.95,"supports":true}
{"relationship_key":"canon-ce788ec64ea9:INCREASES:HGNC:11364","document_id":"PMC5651043","section":null,"start_offset":0,"end_offset":126,"text_span":"The CNTF and STAT3 mRNA levels in the hSCI + BMSC group were markedly upregulated (p < 0.05) compared to the hSCI alone group.","confidence":0.95,"supports":true}
{"relationship_key":"C0022359:INDICATES:canon-93a24f394d4e","document_id":"PMC5579818","section":null,"start_offset":0,"end_offset":226,"text_span":"A 19-year-old woman was scheduled to undergo bilateral sagittal split ramus osteotomy after being diagnosed with a jaw deformity. Preoperative electrocardiography (ECG) revealed a junctional rhythm with a slow heart rate (HR).","confidence":0.95,"supports":true}
{"relationship_key":"C0022390:ASSOCIATED_WITH:C0428977","document_id":"PMC5579818","section":null,"start_offset":0,"end_offset":226,"text_span":"A 19-year-old woman was scheduled to undergo bilateral sagittal split ramus osteotomy after being diagnosed with a jaw deformity. Preoperative electrocardiography (ECG) revealed a junctional rhythm with a slow heart rate (HR).","confidence":0.95,"supports":true}
{"relationship_key":"6387:ASSOCIATED_WITH:C0022390","document_id":"PMC5579818","section":null,"start_offset":0,"end_offset":196,"text_span":"At 90 minutes after anesthesia induction, local anesthesia with 10 mL of 1% lidocaine and 1:100,000 adrenaline was administered. A junctional rhythm appeared 15 minutes after the local anesthesia.","confidence":0.95,"supports":true}
{"relationship_key":"3992:ASSOCIATED_WITH:C0022390","document_id":"PMC5579818","section":null,"start_offset":0,"end_offset":196,"text_span":"At 90 minutes after anesthesia induction, local anesthesia with 10 mL of 1% lidocaine and 1:100,000 adrenaline was administered. A junctional rhythm appeared 15 minutes after the local anesthesia.","confidence":0.95,"supports":true}
{"relationship_key":"3992:INCREASES:canon-dceea34e944d","document_id":"PMC5579818","section":null,"start_offset":0,"end_offset":139,"text_span":"We believe that the atrioventricular nodal pacemaker cells accelerated because of the increased sympathetic activity due to the adrenaline.","confidence":0.85,"supports":true}
{"relationship_key":"canon-dceea34e944d:AFFECTS:canon-cfebd69bf556","document_id":"PMC5579818","section":null,"start_offset":0,"end_offset":139,"text_span":"We believe that the atrioventricular nodal pacemaker cells accelerated because of the increased sympathetic activity due to the adrenaline.","confidence":0.85,"supports":true}
{"relationship_key":"canon-d84b1c693c69:DETECTS:C0022390","document_id":"PMC5579818","section":null,"start_offset":0,"end_offset":226,"text_span":"A 19-year-old woman was scheduled to undergo bilateral sagittal split ramus osteotomy after being diagnosed with a jaw deformity. Preoperative electrocardiography (ECG) revealed a junctional rhythm with a slow heart rate (HR).","confidence":0.95,"supports":true}
{"relationship_key":"C0394648:TREATS:C0020580","document_id":"PMC6727998","section":null,"start_offset":0,"end_offset":224,"text_span":"A reduction in the size of hypoesthetic area with TPI was observed in 27 (58.7%) patients. All the 27 patients experienced a reduction in pain intensity by more than 50% in a numerical rating scale score through TPI therapy.","confidence":0.95,"supports":true}
{"relationship_key":"C0394648:TREATS:C0020580","document_id":"PMC6727998","section":null,"start_offset":0,"end_offset":231,"text_span":"Twenty-seven (90%) patients experienced a reduction in pain intensity by more than 50% in NRS after TPI therapy. In all these 27 patients, a reduction in the size of the hypoesthetic area was observed during the course of treatment","confidence":0.95,"supports":true}
{"relationship_key":"C0394648:TREATS:C0027073","document_id":"PMC6727998","section":null,"start_offset":0,"end_offset":224,"text_span":"A reduction in the size of hypoesthetic area with TPI was observed in 27 (58.7%) patients. All the 27 patients experienced a reduction in pain intensity by more than 50% in a numerical rating scale score through TPI therapy.","confidence":0.95,"supports":true}
{"relationship_key":"C0394648:TREATS:C0027073","document_id":"PMC6727998","section":null,"start_offset":0,"end_offset":231,"text_span":"Twenty-seven (90%) patients experienced a reduction in pain intensity by more than 50% in NRS after TPI therapy. In all these 27 patients, a reduction in the size of the hypoesthetic area was observed during the course of treatment","confidence":0.95,"supports":true}
{"relationship_key":"C0020580:ASSOCIATED_WITH:C0458343","document_id":"PMC6727998","section":null,"start_offset":0,"end_offset":67,"text_span":"Thirty-four (74%) of 46 patients with MTrP had tactile hypoesthesia","confidence":0.95,"supports":true}
{"relationship_key":"C0020580:ASSOCIATED_WITH:C0458343","document_id":"PMC6727998","section":null,"start_offset":0,"end_offset":146,"text_span":"Myofascial trigger points were located in the muscles in the vicinity of ipsilateral cutaneous dermatomes to which the hypoesthetic areas belonged","confidence":0.9,"supports":true}
{"relationship_key":"C0020580:ASSOCIATED_WITH:C0027073","document_id":"PMC6727998","section":null,"start_offset":0,"end_offset":67,"text_span":"Thirty-four (74%) of 46 patients with MTrP had tactile hypoesthesia","confidence":0.95,"supports":true}
{"relationship_key":"C0458343:ASSOCIATED_WITH:C0037658","document_id":"PMC6727998","section":null,"start_offset":0,"end_offset":190,"text_span":"Such inhibition of neuronal activity in the somatosensory cortex induced by ongoing afferent nociceptive input from MTrP may underlie the reversible tactile hypoesthesia in patients with MPS","confidence":0.8,"supports":true}
